ON_Accelerate_9_Showcase_Full_Event

[Music plays and an image appears of a split circle, and photos move through of CSIRO activities in either side of the circle, and then the circle morphs into the CSIRO logo]
[Image changes to show a blue screen with the CSIRO logo on the left, and text appears on the right: ON Accelerate 9, Showcase 5 June 2025]
[Image shows new text: Ideas have the power to…]
[Image changes to show a 3D printer printing]
[Image changes to show a researcher holding up a vial with blue liquid]
[Image changes to show a male having a CT scan with the details of the scan displayed over the image]
[Image changes to show an aerial view of multiple wind turbines spinning as the camera pans up slightly]
[Image changes to show the opening of a CT scanner machine, and text appears: …Change the world]
[Image changes to show a programmable rotator spinning with multiple test tubes]
[Image changes to show an aerial view of a part of a pivot irrigation system watering crops]
[Image changes to show a close view of a 3D printer working]
[Image changes to show a black screen, and text appears: Ideas like these…]
[Image changes to show researchers using an iPad, and then the image changes to show a pipette dispensing liquid into a multi well plate, and text appears: …11 awe-inspiring]…
[Image changes to show a cereal crop waving in the breeze, and text appears: …teams…]
[Image changes to show two males and two females smiling at the camera, and blue text banner appears: …3DCeraFlex…]
[Image changes to show four males smiling at the camera, and a blue text banner appears: …Ability Optics…]
[Image changes to show two males and a female smiling at the camera, and a blue text banner appears: …Amorfoil…]
[Image changes to show two females and two males smiling at the camera, and a blue text banner appears: …Elemental Therapeutics…]
[Image changes to show four males smiling at the camera, and a blue text banner appears: …Enhanced Analgesics…]
[Image changes to show four males smiling at the camera, and a blue text banner appears: …Epiblox…]
[Image changes to show four males smiling at the camera, and a blue text banner appears: …Facet Amtech…]
[Image changes to show four males and a female smiling at the camera, and a blue text banner appears: …I-VADE…]
[Image changes to show two males and a female smiling at the camera, and a blue text banner appears: …ProSeek Bio…]
[Image changes to show a female and two males smiling at the camera, and a blue text banner appears: …TopiCure…]
[Image changes to show a female and five males smiling at the camera, and a blue text banner appears: …Viortec…]
[Image changes to show a robotic automobile tire production machine working automatically as part of a production plant]
[Image changes to show a droplet of clear liquid being injected with a rusty coloured liquid]
[Image changes to show a pipette injecting fluid onto a slide under a microscope, and text appears: …10 affiliate organisations…]
[Image changes to show a blue screen of people walking in the background with the James cook University Australia logo in the foreground]
[Image changes to show a blue screen of a building in the background with the Australian National University logo in the foreground]
[Image changes to show a blue screen of researchers working in a lab in the background with the CSIRO logo in the foreground]
[Image changes to show a blue screen of an aerial view of buildings in the background with the University of Melbourne logo in the foreground]
[Image changes to show a blue screen of a building in the background with the University of Sydney logo in the foreground]
[Image changes to show a blue screen of a building in the background with the University of South Australia logo in the foreground]
[Image changes to show a blue screen of a building w in the background with the University of Newcastle Australia logo in the foreground]
[Image changes to show a blue screen of an aerial view of buildings in the background with the Edith Cowan University logo in the foreground]
[Image changes to show a blue screen of a building in the background with the QIMR Berghofer logo in the foreground]
[Image changes to show a blue screen of a building in the background with the RMIT University logo in the foreground]
[Image changes to show a white pill in a clear container of clear liquid and then the pill spinning fast and dissolving into the liquid, and text appears: Ready to…]
[Image changes to show an aerial view of panel rows on a solar farm as the camera pans in slightly, and text appears: …Shape our future]
[Image changes to show a machine performing analysis testing of multiple tubes]
[Image changes to show an automated pharmaceutical manufacturing line filling vials with a liquid]
[Image changes to show an audience sitting around tables at an ON Accelerate presentation]
[Image changes to show three males and a female working together around a table]
[Image changes to show a male talking with colleagues seated at the” ON Accelerate 9, Enhanced Analgesics” table]
[Image changes to show an audience seated in an auditorium interacting]
[Image changes to show a male in an audience talking into a microphone]
[Image changes to show another male in the audience talking into a microphone]
[Image changes to show a male and female from 3DCeraFlex listening alongside a female as they sit at a table]
[Image changes to show the audience sitting around tables listening, laughing and smiling together]
[Image changes to show a female talking to two listening males]
[Image changes to show a female presenting to an audience in front of a slide between ON Accelerate banners, of a tree and its reflection over a book on the right, the CSIRO logo with text on the left: ON Accelerate, Day 1 Reflections]
[Image changes to show a blue screen with text: Congratulations to all the venture-building teams]
[Image changes to show ON Accelerate colleagues assembled on the stage posing for a photo between ON Accelerate information banners]
[Image changes to show a blue screen with text: ON Accelerate 9 Showcase, Shape our future, Apply now for Accelerate 10 csiro.au/ON]
[The camera zooms out to show an audience applauding in the foreground below the stage and a blue slide with the same text above the stage, and the podium can be seen on the right of the stage] 
[Image shows a new welcome slide with a profile photo of Dr Jen Taylor and her details on the left, and text appears: Welcome, Dr Jen Taylor, Executive Director, Future Industries]
[Image shows Jen walking onto the stage from the right and talking to the audience from the podium on the right of the stage]
Dr Jen Taylor: Well, Good afternoon everyone.
[Image changes to show a medium view of Jen talking at the podium, and text appears: Dr Jen Taylor, Executive Director, Future Industries]
What an exciting day it is and fantastic to see the energy in the room. It's such a pleasure to be with you here today for the showcase, ON Accelerate 9. Wow. It's a fantastic gathering of energy, creativity, intellect, you know, industry vibe and just some clever thinking around how we get our science out into society and in industry so it's a great energy in the room. I hope we all enjoy it this afternoon. 
I would like to begin by acknowledging the traditional custodians of the lands on which we gather today the Wurundjeri, Woiwurrung and Bunurong peoples of the Kulin nation here in Naarm, Melbourne. I pay my respects to their elders, past and present, and extend that respect to any First Nations people joining us this afternoon. In just a moment, we'll actually have a very special welcome video from Dr. Mandy Nicholson from the Djirri Djirri, a Wurundjeri Woman's dance group, and they're unfortunately unable to join us in person here today. But they have very generously recorded a performance to help open our event. Look, we're looking forward to that. 
[Image continues to show Jen talking from the podium]
But to our ON Accelerate 9 cohort, congratulations. What a journey I'm sure you've had. Today is a celebration of that journey that you've been on and all the hard work that you've put into it, the grit, growth and ingenuity that you brought to this moment. And soon we'll hear more about this cohort from Tennille Eyre, ON program director, which will be fantastic, and really looking forward to hearing, I guess, the individual stories from you all as you've taken your ideas from the bench and shaped them into a real scalable opportunities. I actually always find that the really fascinating bit, it's not, it's about the impact journey, but it's also the the personal experiences that come out of a journey like this one. I'm certain that each one of you will have an incredibly unique story to share, and that there will be a a real display of diversity of thinking and creativity in developing impactful ideas and developing pathways to innovation. 
I've had a few experiences with ON. I have not had the privilege of doing an ON Accelerate, but I remember I had a very early experience with a version of the ON program, it was called ON Prime. It was the first year or nearly very much the first year it was run. So it wasn't as intense as the experience that these recent cohorts have been on but for me personally, it was intense enough. So I have a lot of respect for what this cohort has been through. I'm a card carrying introvert, and on the first day I turned up to the facilitator saying I needed to make 100 cold calls to people I didn't know and talk to them about how my science would solve their problem. So after my initial shock, I went away into a very dark corner and spent 30 minutes trying to write out a list of names of people to call, came back with my very brave list of six names.
[Laughter can be heard as the image continues to show Jen talking from the podium]
And tried to tell my facilitator it was about quality, not quantity, and learnt that my negotiation skills weren't very good either. So, anyway, at the end of that experience, my team, we did get to the end with a lot of help. As you know, this is, this is a facilitated journey and that's really important. As a leader of a research group at the time, I left the experience thinking really quite differently about how to shape the research priorities of that group. Although perhaps the most useful thing that has stuck with me since then was the value in getting out of the room, getting out of the lab and having those really direct conversations with potential investors, industry leaders and being really radically open minded about what they're sharing back and valuing that input about how to deliver impact. Being willing to let go of assumptions and even being very willing to kill very long held and precious thoughts that you might have developed for the benefit and that's an, often a very difficult thing to do but I've always found it very rewarding. And also the real importance of creativity and collaboration and how we really cannot create the impact in innovation that we want without that, it's so essential. 
This is the future of Australian innovation, so deep tech that matters, backed by science and built for global markets. I do think Australia has a fantastic opportunity to make the most of what the talents we have here in, in, in Australia. But as all of you know, innovation doesn't happen in isolation, it takes a network. And looking around the room here, we've already got a fantastic network and I'd really like to congratulate the Innovation ON team because it's really fantastic to see who's in the room, how that network is being used across Australia. What a network, really. So our ON teams have also benefited from the support of exceptional facilitators, mentors and coaches. Many are backed by really visionary and highly supportive university partners and technology transfer officers, so important to this journey. 
 [The camera pans in slightly as Jen continues talking from the podium]
And increasingly, we're seeing growing interest from investors and industry leaders who want to be part of that journey. And that's really a sign of, you know, how we're building momentum and scaling. 
I'd like to take a quote from Minister Tim Ayres from his recent address to the Collaborate Innovate 2025 audience recently. The minister said “This is a consequential time for Australia. We must shape the future rather than let us, let it shape us. By aligning research, innovation and industry policy through coordinated national effort, we can build a more resilient, productive and sovereign economy that delivers high skilled jobs and long term prosperity for all Australians.” I found that really quite encouraging that, that we are taking that long term view that we are really seeing, that we do have a very important leadership role to play in Australia and in our region to shape the future that we want. And this kind of, accessing this sort of thinking and also plugging that into collaboration that we see in the room here today as an example, is exactly what the University Research Commercialisation Action Plan aims to accelerate. Through CSIRO's suite of translation and commercialisation programs, including the On program we're working with partners across the ecosystem to ensure great Australian science gets the runway it deserves. 
[Image continues to show Jen talking from the podium]
Quite simply, at CSIRO we believe our job as the National Science Agency is not done until that science is delivering value to Australia and this activity here and you all and your participation is a key part of making that happen. Our role in CSIRO is not just to do great science, but to see that science makes a difference. ON is one of the most visible and powerful ways we do that. It's a privilege to watch these ideas take flight, and to work with the whole innovation system to make this happen. The ON program has such an amazing pedigree of rigour and delivered, and we are very proud of this program. But it doesn't happen without all of you in the room and all your input. 
So thank you all for being part of this showcase and for the role you're playing in helping Australia's innovation system really grow to be a strong, smart, resilient and more connected system. I'm really looking forward to this afternoon and hearing all the stories. 
[Image continues to show Jen talking from the podium as she points up towards the screen behind her]
So without further ado, I'd like to welcome, virtually, I guess, Dr. Mandy Nicholson to the screen.
[Applause can be heard as the image changes to show a black screen]
[Music plays as image changes to show and tall gum trees beside a road in the background, and a large fern on the right in the foreground]
[Image shows Dr Mandy Nicholson  walking in from the right and then looking up at the sky as she turns to face the camera and talking, and the Djirri Djirri logo appears above text over the image: Wominjeka, Welcome]
Dr Mandy Nicholson: [Introduction in Woiwurrung]. 
My name is Mandy Nicholson. I'm a Wurundjeri woman and I also have connections to the Dja Dja Wurrung and Nura language groups of Victoria. 
[Image changes to show a split screen of a male on the left and a female on the right]
What I said in my mother tongue, the Woiwurrung language is that I embrace all of my ancestors, my Liwik.
[Image changes to show Mandy looking at the camera with an older female in the foreground]
I also embrace all of my elders, my grandfather’s and my grandmother's. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees and then the image changes to show a close view of a spiderweb woven in the grass]
I also embraced and acknowledged and helped people understand a little bit more about the different layers of Wurundjeri country. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
The six layers of country for Wurundjeri people represent different elements on a physical level, but also a spiritual level. 
[Image changes to show a young female painted with ochre and wearing traditional dress dancing]
So we've got the Biik-u or below country. 
[Image changes to show young females with older females dancing with ochre painted on their bodies and wearing traditional dress]
That's where we get ochre for celebrations and dance. 
[Image changes to show a profile view of ochre painted female faces looking to the right]
But also we still trade our ochre and we wear it differently when we're celebrating and dancing to when we're in ceremony. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
Then we've got also how the plants, the roots of the plants go into the ground and speak to each other. 
[Image changes to show a view looking up into the canopy of a very tall tree, and then the camera pans down its thick trunk to the ground]
The environment lives in harmony with all these different elements, the insects, the fungus underneath the ground through the root systems, Baban darrang how the mother tree sends her messages to her seedlings and passes on her genetic code. It's a really beautiful thing that we often don't think about is what's under the ground and how it's all working together in harmony. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
The next layer of country is the big Biik-dui, which is on country. 
[Images move through to show a profile view of ochre painted females looking to the left, Mandy talking to the camera, and a group of ochre painted females next to a building smiling at the camera]
So that's where we live our day to day lives but making sure that we don't become unbalanced because we've got our busy day to day working school, sporting lives and our spiritual lives, making sure that our spiritual life doesn't fall to the wayside too much when we're so busy with our day to day lives. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So we make sure that they remain in balance so then we become and maintain our spiritual balance. 
[Image changes to show a close view of rippling flowing water]
Then we've got Baanj Biik, which is water country. So water forms part of everything, gives everything life as we know.
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So it's in our bodies, we drink it. 
[Images move through to show rain cascading down on tall ferns, Mandy talking to the camera beside the tall gum trees, and then a close view of a fast flowing creek through the bush]
It comes from the sky as rain, as Bamabik, but also it's in water vapour as well, up in space and in rivers and creeks and waterways, but also the largest oceans. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So there is water in everything that's living and it's our connector to life. 
[Image changes to show a close view of the bottom of a waterfall pouring into a creek, and then the image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
And we also used to, we can't sadly, anymore because water and country aren't healthy anymore, they’re quite sick. We would gift visitors a drink of water to say that everything is safe while they're visiting. The next layer of country is Murnmut Biik, so you can see the Murnmut blowing in my hair, so it's wind. 
[Image changes to show a small fire’s wafting smoke where Mandy was standing beside the tall gum trees]
So wind blows the smoke from our welcoming fires, but also carries our [indistinct 12.55] or our voice all the way up to our creator. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So in this part of the world, our creator is Bunjil, the wedge tailed eagle. 
[Image changes to show a close view of a wedge-tailed eagle soaring, and then the image changes to show a close view of a Raven flying above water]
And he's got a helper, Awa the raven, so you'll see him everywhere in the urban environment. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So look at him differently now that you know that he's Bunjil's helper. So it also carries all of our songs and language all the way up to Bunjil. 
[Image changes to show a view looking up at the blue sky peeking out from the bush canopy above, and then the image changes to show Mandy talking to the camera beside the tall gum trees]
And it's something that we have to really stop and pause for a minute and take a breath, close our eyes and truly feel that wind, that Murnmut in our hair, feel it on our skin. We need to stop and pause in our busy lives to appreciate that more. 
[Image changes to show a view looking up at the blue sky dotted with Cirrocumulus clouds, and then the image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
Our next layer of country is Wurru wurru biik. Wurru wurru means sky and that's where we see the physical form of our creation being, so Bunjil. 
[Images move through to show a close view of a rainbow lorikeet, a close view of an Australian king parrot, and then a close view of a Nankeen Kestrel flying low over grass]
But we also see Waa the raven, we see [Dundun? 13.44] the parrot, we see [Katubant? 13.46] the King parrot, we see Djurt-Djurt the kestrel and the black shouldered kite. 
[Image changes to show a close view of black-shouldered kite soaring, and then the image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So we see all these beautiful flying creatures and how they are connected to our spirituality and our narrative. So we see them all in their physical form. And the next layer of country is Dharrang gulk biik, so Dharrang is tree, gulk is stick, and biik is country. 
[Image changes to show a colourful dramatic sunset]
So it's the bush country up in the star country, up in the sky at night. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees, and then the image changes to show a milky-way galaxy]
So when you delve into breaking down language like that, you can work out all of this beautiful cultural knowledge that's been hidden from us for such a long time. 
[Images move through to show Mandy talking to the camera, a sepia photo of children assembled with a dog at the front, and a large group of ochre painted females in traditional dress] 
And language is the key to unpicking that and unravelling that and relearning stuff that we weren't allowed to learn for the past three generations in my community, in the Wurundjeri community and also the rest of First Nation people around the world in the 1800s when this happened. Culture, language, ceremony, especially women's and gendered ceremonies stopped happening. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees, and then the image changes to show a milky-way galaxy in the night sky above a small fire]
So when we look at the stars, we look and read the stories and the narrative up in the stars and understand that whatever's up there in the stars is totally reflected exactly down here on Earth. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
So if you take any of those layers, pick them out, pull them out, nothing can survive. So we really need to look at things differently in country. We need to make sure that we look after countries. So when I welcome people to country it isn't about saying, hey, you're welcome, have a good time. It's about cultural obligations as a traditional custodian, myself, making sure that I look after you spiritually while you're on country, but it's also cultural obligations from you. So if you do acknowledgements, change it up. Make it unique to yourself. Say that I live on Bunurong country, but I work on Woiwurrung or Wurundjeri Country. Things like that make it unique and the difference between an acknowledgement and a welcome is a welcome means that spiritual and cultural obligation of a leader in their community has to gift you that understanding of why and how, and how you can fit into the environment around you while you're visiting their country. So it's really important to understand those little intricacies and different ways that you can connect while visiting. 
[Image continues to show Mandy talking as she bends down and picking up a gumleaf and then studying it as she talks]
For example, if you wanted to pick up a gum leaf, look at that gum leaf, look at the detail in that gum leaf. 
[Image changes to show a close view of gum leaves]
Make sure you look at it like a little baby would, and then you start to read that leaf. So you'll see all these beautiful little veins, little lines, little patterns and colour. 
[Image changes to show a close view of a yellow and red splotched dying gum leaf fallen on the ground]
And then you can compare those veins on a bigger picture to the veins in your arm. 
[Image changes to show of Mandy talking to the camera, and then the image changes to show a fallen tree trunk across a creek as the camera pans down and to the right as rippling water flows past]
And then you go bigger, even bigger, and compare those veins to like waterways over country. So that's one way that you can visually and change visually actually what you and how you look at things while on country or when you're out and about. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees crushing the leaf in her hands and then smelling it, and then she continues talking again]
Another way is to get a gum leaf and crush it up. And even when it's old and dead like this one, it still holds that eucalypt oil. 
[Image changes to show a small fire’s wafting smoke where Mandy was standing beside the tall gum trees]
So that is the key to when we do our smoking ceremonies. We put the leaves on the fire. We block the oxygen off, we change that smoke into a white tufty smoke and it releases and steams those green gum leaves to release that eucalyptus oil. 
[Image changes to show a wide view of Mandy talking to the camera beside the tall gum trees]
And we know, and we've always known the healing properties found within eucalyptus, the antiseptic qualities, how it clears our lungs when we're sick. So there's another way that you can connect to country. 
[Image shows Mandy looking up at the sky and then she continues talking again]
We're going to listen to country now and be quiet for a minute. 
[Birdsong can be heard as the image changes to show large trunks in the foreground of a bush with ferns and tall gums, and then the camera pans up the trunk to the tree canopy and blue sky]
[Image changes to show the wide base of an old tree trunk as the camera pans up the trunk to the tree’s canopy and blue cloudy sky]
This is what everyone needs to do. Go out into the bush and just be still. Forget about everything else that's going on. Truly feel country. Take your shoes off. Feel the sand between your toes. Feel the mud. And make sure you feel those vibrations around you. 
[Image changes to show a bush track between two tall ferns, and then Mandy walks in from the right through the ferns]
The bugs flying around the sun. Coming through, mottled through the trees. The little bits of wind. The different birds. Different times of day. Different types of birds. If you come here before the sun rises, you'll hear. 
[Music plays as The camera zooms out to show the audience looking at a new slide with a photo and details of Tennille Eyre above the stage with the podium on the right, and text appears: Tennile Eyer, Program Director, ON Innovation Program]
[Image shows Tennile standing up from the centre of the audience and walking over to the right and then walking onto the stage and then talking to the audience from centre stage]
Tennille Eyre: Good afternoon, everyone. 
[The camera zooms in to a medium view of Tennille Eyre as she continues talking from centre stage, and text appears: Tennille Eyre, Program Director, ON Innovation Program]
Slightly premature call to the stage, but there was only another brief moment, so thank you for taking that moment to observe country from these very corporate grounds, but appreciate the moment of peace and calm that that brought to us. 
[Image continues to show Tennille talking from centre stage as she points at the audience]
I do want to start by extending, extending my sincere thanks to Dr. Jen Taylor, our executive, for her support and ongoing encouragement and continued leadership in this space. And you've lived it, and you have an unwavering belief in the ability and the power of research translation to drive real world impact. 
[Image continues to show Tennille talking from centre stage]
And how gorgeous was that video? I know I was taking a moment to sort of ground myself and breathe, and I'm sure the cohort have done the same who were about to present. So our sincere thanks to Dr. Mandy Nicholson and our friends from the Djirri Djirri for that special welcome to country and acknowledge country today on such beautiful lands here in Naarm. 
So today is a celebration of our incredible ON Accelerate 9 cohort, what we've achieved together as program leads but also this community, as Jen mentioned. And as you'll hear me, incredibly valuable partners that have participated in the program support us and you're all passionate champions of innovation and science led change. 
Now, I've been with the program for the better part of a decade and I take the moment before we come to events like this to sort of reflect on what I take away from each round and each year. Some words that come to mind are connections, friendship, empowerment and always a bit of fun. I've seen journeys of self-discovery, I've seen personal growth. We've seen health scares, we’ve seen babies born. Imposter syndrome, complete role changes, team building challenges, spin outs, spin ins, spin downs and global expansion. It’s, it is a rollercoaster and it's one I get on all the time, year after year, and I'm so excited to be able to stand up to that plate. 
[Image continues to show Tennille talking from centre stage]
Conversations that happen here, they could be conversations at 3:00 a.m. waiting in the Perth lounge to get back home on a flight after we've run a session in, on the West Coast or conversations at 3:00 a.m. a different kind of red eye, bleary eyed at the pub, having these conversations and connecting with your peers. These conversations mould and shape who you are, how you think. They challenge your thinking. They've helped me, and I know many of those of you in the room form relationships that I know will be with me for life. And they're going to empower you through the tough stuff, but they're also going to be the people that are going to celebrate you, with you through the wins. And while the Djirri Djirri people have welcomed you to this incredible country, it's my job today to welcome you into this community. 
So welcome to the ON Accelerate 9 cohort into possibly one of the best communities in the world, in my opinion. They're great. They're open minded, they're kind and they're caring. They are warm, with a passion to see you succeed. You will never find yourself in a room that is more ready to back you and support you to have success. But they're also going to challenge you when you're being that little bit stubborn and you need some help to see through the cloud. They'll do that respectfully, but they're absolutely wise and incredible words of wisdom. 
[The camera zooms out to show the audience listening in the foreground as Tennille continues talking from centre stage, and the slide changes to show colleague posing for a photo on stage]
So ON Accelerate exists to support and help Australian research make its way from the lab to market. It helps with confidence, clarity and of course, collaboration. 
[The camera zooms in to a medium view of Tennille Eyre as she continues talking from centre stage]
And this year we've seen one of our most commercially focused and globally ambitious cohorts yet. These teams are tackling some of the biggest challenges of our time, across areas of drug development, healthcare delivery and sustainable technologies. They're developing new drug candidates for conditions like chronic pain, epilepsy and bacterial pneumonia. They're reimagining diagnostics with tools like blood test for early stage ovarian cancer. They're transforming healthcare training with VR based aggression de-escalation programs powered by AI. And they're pushing the boundaries of deep tech from energy efficient ammonia production. They're revolutionising amorphous steel production to strengthen Australia's energy grid. They're advancing orthopaedic implants for hip and knee surgeries. And these aren't just incremental advances. They're frontier technologies backed by research, driven by purpose and they're absolutely designed for global impact. 
[The camera zooms out to show the audience listening in the foreground as Tennille continues talking from centre stage]
And I would like to call out some great achievements that this, this cohort have already achieved. 
[Image continues to show Tennille talking to the audience from centre stage, and a new slide shows 11 team photos of the ON Accelerate 9 teams with their names]
Elemental Therapeutics and TopiCure are recipients of the 2025 AEA Ignite grant. 
[The camera zooms in to a medium view of Tennille Eyre as she continues talking from centre stage]
Facet Amtech has joined the New South Wales Going Global Program, secured CSIRO Kickstart and Industry Growth Program funding, and has successfully spun out of the University of Newcastle. I-VADE have been accepted into the Microsoft for Startups Founders Hub and have received nearly $500,000 from the Western Australia Future Health Research and Innovation Fund to scale their VR tech. Enhanced Analgesics and Facet Amtech have filed patents for their technologies, which as you all know, is a critical milestone to spinning out of their organisations and the path to commercialisation. 
Overall, these 11 teams have raised a total investment and funding of $33.8 million. They've had over 500 investor and industry conversations while in program, Jen. 
[Image shows Tennille laughing and then she continues talking form centre stage]
And behind these milestones, these are founders and researchers, that they've worked with grit, determination and tenacity but also generosity. And we can't be prouder of your progress. 
So to all of our industry partners and investors, if something tonight captures your attention, we and these teams would love to speak to you. These teams are looking for customers, they’re looking for pilots, co-development, partnerships and any obviously funding that supports their solutions to get to the next stage. 
[The camera zooms out to show the audience listening in the foreground as Tennille continues talking from centre stage, a new slide shows a blue screen with text: Standford Australia Foundation Hawkins Ueland CSIRO Scholarship]
Now we're also grateful to continue our partnership with the Stanford Australia Foundation. 
[The camera zooms in to a medium view of Tennille Eyre as she continues talking from centre stage]
We're going, we continue to provide selected ON participants with the opportunity to explore global approaches and innovation for entrepreneurship. This experience continues to inspire bold thinking and long term vision among our cohorts. We'll be announcing the winner of the 2025 Stanford Australia Foundation Hawkins Ueland Scholarship at the conclusion of today's presentations. 
[The camera zooms out to show the audience listening in the foreground as Tennille continues talking from centre stage, a new slide shows a blue screen with a QR code above text: Help us shape the future of inclusive innovation in Australia]
But ON is about more than just science translation. 
[The camera zooms in to a medium view of Tennille Eyre as she continues talking from centre stage]
We have a responsibility to build an innovation ecosystem that reflects diversity, creativity and the potential of Australia. That's why we're so proud to partner with the Global Institute for Women's Leadership and the Wiyi Yani U Thangani Foundation at ANU to understand how we can all shape a more inclusive, equitable and impactful innovation ecosystem. And programs like ON can, and we absolutely must, lead the way in fostering innovation and diversity in in our innovation future. 
[Image continues to show Tennille talking from centre stage as she points up at the screen behind her]
So there's a QR code behind me. If you want to help that future of innovation, inclusivity and diversity, scan this code and you'll be able to find out ways that you can get involved. I'll leave that pause for a moment. 
[Image continues to show Tennille talking from centre stage pointing up and to the left of the auditorium]
We'll have more for you upstairs, so more information on that for you over at our booth. 
[Image continues to show Tennille talking from centre stage]
So how the presentations are going to run today, I'm about to exit stage and we will welcome our first team onto stage. You're going to hear 11 fantastic stories of these incredible teams and their journeys so far. We'll start with a video and those videos are so fantastic, I know you're going to want to applause, but once the video concludes, someone's going to be on stage straight away. If you wouldn't mind holding your presentation, sorry, your applause until they've completed their presentation and then be as loud and as joyous as you can be. 
First up, the team that we'll be speaking today are going to be the ones who are supporting our incredible healthcare workers in their capability and training development. So let's get ready. Are you all ready before we go? 
[Image continues to show Tennille talking from centre stage as she points to the right of the stage]
Let's have a huge round of applause for Team I-VADE who are going to be first on stage. But congratulations team, and an applause if you wouldn't mind, to celebrate and kick off.
[Applause can be heard as Tennille applauds and then walks to the left of the stage]
[Music plays as the image changes to show a blue screen with the CSIRO logo on the left, and text appears on the right: ON Accelerate 9, Showcase 5 June 2025]
[Image changes to show a white screen with a blue heading text box: Meet]
[Image changes to show a blue screen with heading text expanding: I-VADE]
[Image changes to show a female putting on a VR headset, and text appears: A ground breaking VR-based…]
[Image changes to show a person screaming on the right and text appears on the left: …de-escalation training solution]
[Image changes to show three healthcare workers wearing IDs standing outside of a building, and text appears: Enabling healthcare workers…]
[Image changes to show a healthcare worker using a VR headset and remote, and an inset of the VR headset’s animation of a male beside a bed can be seen on the right, and text below the inset image: …to practise and prefect…]
[Camera zooms in on the VR inset animation, and an action bar appears of suggested phrases to use in the situation, and text appears: … their responses…, Tell him to wait, Tell him to calm down, Ask why he is here today] 
[Image changes to show the animated male becoming aggressive, and text appears on the right: …to aggressive and violent patients…]
[Image changes to show an older male using the VR headset and remote, and text appears: …in a safe environment]
[Image changes to show colleagues sitting around a small table with clipboards in discussion, and text appears: Co-designed…]
[Image changes to show a blue screen with text: …with healthcare professionals]
[Image changes to show a white screen with a blue heading text box: Featuring…]
[Image changes to show a male using a headset in the foreground that transfers his body’s motions onto the avatar in the background, and text appears: …advanced motion capture…]
[Image changes to show a close view of the male wearing the headset  talking angrily on the right, and the animated avatar copying him on the left, and text appears: …and AI-driven avatars…]
[Image changes to show an animated avatar male looking stressed and talking angrily, and text appears: …to simulate high-pressure, real-world environments]
[Image changes to show a male taking off a VR headset while talking to a female using a laptop, and text appears: Setting a new standard…]
[Image changes to show a male pointing to a computer with the VR simulation on the right, and text appears on the left: …for global healthcare training]
[Image changes to show a blue screen with a white heading text box: Developing…]
[Image changes to show three insets images of a female taking a swab on the left, a male smiling at the centre, and a female smiling at the camera on the right, and text appears: … safer, happier, more confident…] 
[Image changes to show a white screen with text: …healthcare professionals]
[Image changes to show researchers working in a lab, and text appears: Delivering better care]
[Image changes to show a blue screen with text: Lowering staff turnover]
[Image changes to show four healthcare workers conversing as they walk towards the camera, and text appears: Creating a stronger, healthcare system, for everyone]
[Image changes to show an inset of a male wearing a VR headset, then another male appears in the background on the left of the inset, and text appears on the far left of the screen: With I-VADE safety isn’t just policy…] 
[Image changes to show a white screen with text: …it’s a reality]
[Image shows new text: I-VADE, www.alphaimmersion.org]
[The camera zooms out showing the audience in the foreground, Dr Brennen Mills walking onstage and talking, and a new slide shows an ECU and Immersion logos below text: I-VADE, Virtual Reality Training for violence de-escalation in healthcare]
Dr Brennen Mills: Hello everyone. 
[The camera zooms in to a medium view of Brennen as he continues talking from centre stage, and text appears: Dr Brennen Mills, I-VADE] 
The concept of I-VADE was brought to me and my team, a team of virtual reality and healthcare experts, by hospital clinicians with a vision of how this technology can help solve what is just a relentless problem for them, and that is the everyday exposure to patient related aggression and violence. 
[The camera zooms out showing the audience in the foreground listening to Brennen talking on stage, and videos play on the screen from 7News of physical violence towards healthcare workers]
Most of us know someone who is a nurse, a doctor or a paramedic. Go ask them the extent that they experience this on a daily basis. You'll be blown away by the stories they have to tell you. 
[Image continues to show Brennen talking as a new slide shows a female sitting with her head in her hand and then the camera zooms in to a medium view of Brennen as he continues talking]
Imagine the kind of toll this everyday exposure would take over weeks, months, years. Given this, is it really surprising that a quarter of the nursing workforce are planning on leaving the profession in the next 2 to 5 years? With all of this experience walking out the door, our customers are telling us the number one issue they are focused on right now is health workforce retention. 
[Camera zooms out to show the audience in the foreground, Brennen talking centre stage, and the slide shows the female and a left pointing arrow between text appears on the slide: Health workforce retention, Exposure to aggression and violence] 
We need to be doing absolutely everything we can to get these guys in the job for longer. And there is a keen acknowledgement that exposure to aggression and violence is one of, if not the most prolific contributors impacting health workforce retention. 
[The camera zooms in to a medium view of Brennen as he continues talking from centre stage]
My name is Dr. Brennen Mills and with I-VADE my amazing team and I are changing the way the healthcare industry thinks about clinician preparedness, empowering them to de-escalate incidents before they turn violent. Virtual reality provides an until now untapped pathway for us to do this with greater efficiency, flexibility and scalability. 
[Camera zooms out to show the audience in the foreground, Brennen talking, and a new slide showing a male using a VR headset on the left and an angry male avatar talking on the right] 
[Image continues to show Brennen talking to the audience, and a new slide showing an angry male and an avatar copying him, and the camera zooms in to a medium view of Brennen talking] 
Through extensive co-design with health industry and de-escalation experts I-VADE provides clinicians an opportunity to practice core de-escalation skills in psychologically safe settings, making use of virtual patients brought to life through cutting edge motion capture technology. 
Through trials with more than 700 health clinicians and students to date at 14 sites across Australia, we now have published evidence demonstrating powerful improvements in clinician confidence and preparedness within the first 15 to 20 minutes interacting with I-VADE. 
31.51 [The camera zooms out to show the audience in the foreground, Brennen talking from centre stage, and a new slide showing an I-VADE headset on the right, and text appears on the left: Prototype trials, -700+ health professionals, -14 sites across Australia, -Confidence improvements within first 15-20mins, -9/10 want more I-VADE training]
We have clinicians coming to us with 20 years experience telling us that their whole, the whole way they approach these incidents has changed. Nine out of ten trial participants want more I-VADE training. 
[Images move through to show Brennen talking to the audience from centre stage, and then a medium view of Brennan talking, and a new slide shows a male talking on the left, and text appears: “The importance of this training cannot be under-estimated.”, Simon Trowler, Chief Medical Officer, Department of Health WA]
The success of these trials has led the WA Department of Health to invest $1 million cash in commercialisation funding to make I-VADE available for their staff. We've also been accepted into the Microsoft Founders Hub, putting us on a pathway to access 140 markets globally. We've already managed to attract keen interest in both the US and the UK. 
But what do we need right now to realise all of this incredible potential? 
[The camera zooms out as Brennen continues talking to the audience from centre stage, and a new slide shows plants growing on stacks of coins, and text appears on the left: How can you help?!, -Seeking to raise $300k, -Finalise software development, -Deployment ready, -Rollout with foundational customers]
We're seeking to raise $300,000 seed, which will allow us to finalise software development and become deployment ready so we can roll out our full I-VADE suite with our foundational customers in early 2026. 
[Image continues to show Brennen talking to the audience from centre stage, and a new slide shows a female wearing a VR headset on the right and an angry male on the left below text: I-VADE, Dr Brennen Mills (PhD), b.mills@ecu.edu.au]
So look, if you'd like to learn more, please come over and join us at our booth. We'll be in some nice royal blue polos that we spent 25 bucks on just the other day. Worst case, you're going to come over, you can try the demo. 
[The camera zooms in to a medium view of Brennen as he continues talking from centre stage]
You might get abused by a virtual patient named Derek who's having a bad day. But best case, you might actually end up joining us in protecting those that sacrifice so much to care for us and our loved ones. 
[Camera zooms out to show Brennen talking to the audience from centre stage and the same slide can be seen on the screen in the background]
Thank you. 
[Applause can be heard and music plays as the image shows Brennen exiting the stage to the left and walks across the room to the right, and then a new slide shows a white screen with the ECU logo]
[Image changes to show text screen and then an animation image of a male coughing and text appears on the text screen: In the time it takes to watch this video, 8 people will be diagnosed with an antibiotic-resistant infection] 
Narrator: Imagine you have a nasty chest infection. 
[Animation image shows a pill dropping from the top of the screen, the male catching the pill and then tossing it into his mouth]
You go to the doctor and take some antibiotics, but they don't work. 
[Animation image shows the male coughing again]
Instead, you get sicker. 
[Animation image changes to show various forms of bacteria and small circles appearing around a central bacteria, and then Antibiotic tablets bouncing of the encircled bacteria]
Bacteria are developing resistance to existing and emerging antibiotics, reducing their effectiveness. 
[Animation image changes to show the Earth slowly rotating, and text appears above a line pointing at the Earth: Antibiotic Resistance]
This is antibiotic resistance, a global health crisis which can affect anyone, anywhere. 
[Animation image shows the Earth morphing into a ticking clock]
In fact, every 11 seconds someone is diagnosed with an antibiotic resistant infection. 
[Animation image shows the clock hands morphing into numbers counting up from 30M up to 39M above text: by 2050]
By 2050, it will kill more than 39 million people. 
[Animation image changes to show a circular diagram with a doctor at the centre surrounded by an  apple, phone call, stethoscope, heart and a medical bag symbols, and encircled by various customers]
That's why we're developing a new class of antibacterials to protect our ability to treat common infections. 
[Animation image changes to show a blue screen with a white circle, and text appears at the centre: PBT2]
Introducing PBT2, an innovative drug that restores antibiotic power using the body's own zinc. 
[Animation image changes to show a PBT2 tablet hitting an encircled bacteria cell, removing the protective circles, and then an antibiotic tablet hitting the bacteria, and text appears: Zinc] 
PBT2 rapidly transports zinc into bacterial cells to overwhelm pathogens. 
[Animation image changes to show a blue screen with three flower shapes with a doctor, a cross, and a medical bag symbol inside, and text appears: Increased Confidence, Fewer Failures, Less Hospitalisation]
When taken with antibiotics, it disrupts resistance mechanisms to clear the infection without promoting resistance, meaning greater confidence in prescribing, reduced treatment failures and fewer hospitalisations. 
[Music plays as image changes to show a blue screen with text: Elemental Therapeutics, www.ElementalTherapeutics.com.au]
Elemental Therapeutics, ensuring antibiotics work first time, every time.
[Camera zooms out to show the audience in the foreground, and Ella Casale walking onstage and talking, and then the camera zooms in to a medium view of Ella, and text appears: Ella Casale, Elemental Therapeutics]
Ella Casale: As you've just heard, our antibiotics are failing. And if we zoom in on one key disease area for patients with community acquired pneumonia, the impact of this treatment failure can be life threatening. 
[The camera zooms out as Ella continues talking from centre stage, and a new slide shows a blue screen with text: Antibiotics are failing, First time, every time]
But what if we could prevent these antibiotics from failing and ensure these drugs work first time every time, even against drug resistant infections. 
[Image continues to show Ella talking to the audience from centre stage, and then the camera zooms in to a medium view of Ella, and a new slide shows a researcher working in a lab, and text appears: Restoring the power of antibiotics, Ella Casale] 
Hi I'm Ella. I lead our operations at Elemental Therapeutics and I want to talk to you more about PBT2, a small molecule oral therapeutic that you take with antibiotics restoring their efficacy. So how does PBT2 work? Well, during infection the body uses zinc as part of your natural immune response. The problem is bacteria can pump this zinc out faster than our bodies can pump it in. 
[The camera zooms out as Ella continues talking from centre stage, and a new slide shows a cone protruding from a male’s stomach and an antibiotic pill and Zinc from a PBT2 pill going into the cone]
PBT2 solves that by rapidly transporting zinc into bacterial cells, and when taken with antibiotics, it disrupts the bacteria's ability to resist these drugs, clearing the infection. 
[Image continues to show Ella talking to the audience from centre stage, and then the camera zooms in on Ella talking, and a new slide shows a shield symbol and text heading and text appears: Key features & benefits, Safe] 
PBT2 is safe as it treats phase two clinical trials for neurodegenerative diseases. It's got low manufacturing costs and it's also available in oral form so it can easily fit into current clinical practice. Importantly, it works. It's meaning that our antibiotics will work first time, every time and we've also seen no development of resistance and that's a really key competitive advantage. 
[Image continues to show Ella talking, and then The camera zooms out as Ella talking to the audience from centre stage, and five new symbols appear on the same slide and new text appears: Low Manufacturing Costs, Easy to Administer, Efficacious, No resistance, Patented] 
Finally, our IP is patent protected with a broad method of use patent and this is granted in key jurisdictions. And we've also got a long term IP strategy in place to maximise our market exclusivity. 
[Image continues to show Ella talking to the audience from centre stage, and then the camera zooms in on Ella talking, and a new slide shows a nested circle graph, and text appears on the left: US Community Acquired Pneumonia Patients, Conservative 10% uptake = 142K patients per year]
In the US alone there are about 4.7 million cases of this disease every year. And if we focus on patients with risk factors for drug resistance and account for a conservative 10% uptake, this leaves us with an initial base of 142,000 patients per year. In financial terms, that's an addressable market of up to 190 million USD, again, this is in the US alone. 
[The camera zooms out as Ella continues talking to the audience from centre stage]
This is our beachhead in terms of our lead target market and our initial indication but we've got significant opportunities for global expansion across other disease areas. 
[Image continues to show Ella talking to the audience from centre stage, and a new slide shows a quadrant alignment chart on the right, and text appears on the left: Competitors, The key in the respiratory space, The competitive landscape information presented here is based on publicly available data and our interpretation of the market of the data presentation. This analysis may contain estimates or opinions. All trademarks and brand names are the property of their respective owners]
We're uniquely placed to enter a new space in the market. 
[The image continues to show Ella talking to the audience and the camera zooms in to a medium view of Ella as she continues talking, and text appears on the Last Resort line on the chart: Omadacycline, Lefamulin] 
Traditional antibiotics such as Omadacycline, Lefamulin, these are listed as drugs of last resort by the W.H.O. And what that means is their use will be limited and they'll also come at a high cost. Non-traditional agents are currently being developed in IV form only, whereas PBT2 is available in oral form, and that's a key gap in the pre-clinical development pipeline. 
We're currently in lead optimisation and that's supported through non-dilutive funding, and we're looking to move into pre-clinical in the second half of this year. 
[The camera zooms out as Ella continues talking to the audience from centre stage, and a new slide shows a blue screen with text: Our Ask, $1.5M AUD, 30% of our preclinical development costs, Commercial Advisor]
Currently, we're seeking $1.5 million in this initial equity round and we're also looking to build out our commercial advisory team. 
[Image continues to show Ella talking from centre stage, and a new slide shows profile photos of the six team members with details and two supporting companies with contact symbols, and text appears: Team, Christopher McDevitt, CSO, Ella Casale CCO, Bliss Cunningham, Head of R&D, Clare Moran, Research Officer, Kaitlyn Martin, Research Support Officer, Rachel Cass, Technical Officer, Connect with us, ETx-Team@unimelb.edu.au, elemental-therapeutics-au, ElementalTherapeutics.com.au]
Our team combines scientific and operational expertise, which makes us really well placed to de-risk PBT2. 
[The camera zooms in to a medium view of Ella as she continues talking from centre stage]
Connect with us to help ensure that antibiotics work first time, every time. Thank you. 
[Applause can be heard as the camera zooms out to show the audience in the foreground applauding Ella as she exits the stage to the left]
[Music plays as Ella walks across the room in front of the stage to the right, and a new slide shows a blue screen with The University of Melbourne logo] 
[Image changes to show a black screen with the Ability Optics logo]
[Image changes to show an animation of lab equipment testing samples, and then the image changes to show a graph of Potential Cancer treatments over 555 days with increasing costs]
Narrator: With more than 100 different types of cancer, and drug developments being slow and costly, effective personalised treatments are rare. 
[Animation image changes to show a green cancer cell as the camera slowly pans in on the cell]
Conventional imaging tools struggle to distinguish cancer cells buried deep within dense organ models, making precise drug targeting impossible. 
[Animation image shows the cell morphing into a clear cell encasing blue tissue as the camera slowly pans in on the cell, and text appears: 100x Faster]
We've developed a suite of technologies that map hidden cells and drug targets 100 times faster than existing solutions. 
[Animation continues panning in on the blue tissue inside the cell, and then a white box appears magnifying the tissue further as the camera continues to pan in on the tissue]
Using advanced computational imaging we transform existing microscopes into live, high resolution 3D explorers by sculpting light inside cell clusters and automatically correcting for distortions in real time. 
[Animation images move through to show a red cell changing to blue and growing smaller amongst tissue as a clock appears on the right, and then a lower cost 5 day Potential Cancer treatments graph]
We empower researchers to explore and locate cancer cells, reveal hidden behaviours, and track their response to drugs over time, accelerating cancer research breakthroughs and unlocking entirely new avenues for targeted cell therapy discoveries while fast tracking the screening process for drug development, significantly reducing the time and cost required to get them to market. 
[Image changes to show a black screen with the Ability Optics logo above text: www.abilityoptics.com]
With Ability Optics, the difference is clear.
[Image changes to show Daniel Lim standing at centre stage, and then the camera zooms in on Daniel talking to the camera, and a new slide shows two DNA molecules, and text appears: First-in-class mRNA pain therapy, A University of Sydney Spinout, Daniel Lim, Ability Optics]
Daniel Lim: Hi, I'm Daniel Lim from Ability Optics. I want you to take a moment to consider the people around you. 
[Camera zooms out as Daniel continues talking to the audience, and slides flick through to show the ON Accelerate slide, a microscopic view of cell tissue, and bike riders and text appears: Transforming Microscopy for Advanced Bioimaging, Ability Optics, Almost one in two Australian men and women will be diagnosed with cancer by the age of 85] 
Unfortunately, chances are one of you will be diagnosed with cancer during your lifetime. With over 100 different types of cancer, we need to find new drugs to help cancer patients. 
[The camera zooms in to a medium view of Daniel as he continues talking from centre stage]
And this is still a problem because it can take ten years and millions of dollars just to find a drug for one type of cancer. 
[The camera zooms out as Daniel continues talking from centre stage, and a new slide shows a flow chart of the process of traditional screening time for a drug to be used on found cancer, and text appears: Discovering a drug that works is like finding a needle in a haystack]
And one of the reasons for this is a test would involve taking an image to determine if a drug reduces the size of a tumour, a process that can take 555 days for 100,000 tests. 
[Image continues to show Daniel talking from centre stage, and the slide shows a new flow chart of the process of Hyper-HTS screening time for a drug to be used on found cancer, and text appears: Finding that needle in a haystack is 100x faster with Hyper-HTS]]
That is why at Ability Optics we developed a solution to this problem. 
[The camera zooms in to a medium view of Daniel as he continues talking from centre stage]
Hyper-HTS is a device that screens drugs 100 times faster than existing technologies, reducing that screening time down to just five days. Our technology is behind Hyper-HTS, it’s backed by two national phase patents and over two years of external validation by more than 50 users. 
[The camera zooms out as Daniel continues talking, and a new slide shows symbols of a pen and clipboard, conversations, a handshake and paper and people in conversation, and text appears: Well positioned to capitalise on our innovation, 2 national phase patents, Validation in market 50+ users over 2 years, Commercial engagement with global microscope companies, +30 potential customers]
With the support from the ON program we have established long standing relationships with major microscope companies and 30 more potential customers. 
[Images move through to show Daniel talking from the stage, and a medium view of Daniel, and a new slide shows a quadrant chart of company categories for speed and clarity, and text appears: Globally relevant and competitive] 
Notably, our technology stands out from the crowd, by seeing drugs penetrate deep into tissue faster and clearer. We are effectively reducing the cost of screening drugs. Following our competitive advantages, we are tackling a market worth $25 billion, and we reckon that we can tap into $500 million from this market. 
[Camera zooms out as Daniel continues talking from centre stage, and a new slide shows symbols of a microscope, a researcher, a handshake over a document, arrows and a calendar between text: Revenue Models, Direct Hardware Sales, Research Imaging, Contracts, Technology Licencing, Software Licences and Maintenance]
Indeed, we have a product that is already in market, and we are continuing to pursue other revenue models, ranging from imaging contracts to software licences. 
[Images move through to show Daniel talking from centre stage, a medium view of Daniel talking, and a new slide showing four team members’ photos and supporting company logos, and text appears: 80+ Years Experience Optics and Biomedical Research, Executive Team, Scientific Advisory Board From Leading Institutions, Dr Klaus Matzger, Dr Francois Rigaut, Dr Tri Phan] 
And part of this success is because of the team that we have assembled. Our team has over 80 years of combined experience with optical engineering, business development and biomedical research. So where are we heading to next? Well, we would like to see our technologies in the hands of labs that are saving lives. 
[The camera zooms out as Daniel continues talking from centre stage, and a new slide shows a microscope, networking, and a hand holding money and cog symbols on the right, and text appears on the left: Help us take drug discovery to the next level, Get in touch with us hello@abilityoptics.com, What we’re looking for, Customer contacts, Networks and expertise in the pharmaceutical space, Funding opportunities]
And to do this we are seeking for the next sales customers, networks in the pharmaceutical space, which hopefully will be some of you amongst the audience, and we are looking for other funding, potential funding opportunities to accelerate our path to market. 
[The camera zooms in to a medium view of Daniel as he continues talking from centre stage]
So if you're interested in taking drug discovery to the next level, come and speak with us. Thank you. 
[Applause can be heard and then music plays as the audience applauds Daniel as he exits the stage to the left and walks across the room to the right, and a new slide shows the ANU logo] 
[Image changes to show a close view of a male rubbing the back of his neck with his hand, and text appears: 1 in 5 adults suffer from chronic pain]
Narrator: Did you know 1 in 5 adults suffer from chronic pain? 
[Image changes to show a close view of an elderly female’s eyes looking down and then up at the camera, and then multiple images of various people cover her eyes, and text appears: Over a billion lives affected]
Globally, that's over a billion lives affected and most don't find relief from existing treatments.
[Image changes to show a darkened image of hands pressing a pill out of a medicine packet and then lifting the pill up, and text appears: Don’t’ work, Cause side effects, Addiction]
Current painkillers either don't work, cause harmful side effects or lead to addiction. 
[Image changes to show views of a DNA molecule slowly rotating, and text appears: mRNA ]
But recent breakthroughs in molecular science and mRNA delivery have unlocked a revolutionary approach. 
[Image move through to show liquid being syringed into a test tube tray, sample test tubes rotating in a piece of lab equipment, and a researcher using a syringe, and text appears: Enhanced Analgesics, The world’s first mRNA-based painkiller, Targeted relief, No opioids]
Introducing Enhanced Analgesics, the world's first mRNA based painkiller delivering targeted relief without opioids. 
[Image changes to show an elderly female using a nasal spray, and then the image changes to show a hologram of a person’s head and a nasal spray bottle squirting and releasing dots into the nose]
A simple nasal spray guides the body to produce its own pain blocking molecules based on a modified version of a gene we all have. 
[Camera pans in and rotates slowly to the left as the dots released from the bottle float to the brain area]
The natural painkiller is produced in the nose before crossing into the brain, where it provides long lasting pain relief with a single dose. 
[Images move through to show various a close views of a variety of people smiling at the camera, a couple embracing, and then a three way split screen of people smiling at the camera]
We're transforming pain treatment for millions, helping patients regain their lives, providing doctors with safer tools and giving families peace of mind. 
[Image changes to show a white screen with text: Enhanced Analgesics, Find out more EnhancedAnalgesics.com]
Join us and help make the future of pain relief a reality.
[Image changes to show Prof. Greg Neely walking on stage from the right of the stage, and then he begins talking to the audience from centre stage below the previous slide about Enhanced Analgesics]
Prof. Greg Neely: Hey guys. 
[The camera zooms in to a medium view of Greg as he continues talking from centre stage, and text appears: Prof. Greg Neely, Enhanced Analgesics]
Thanks for coming today. My name is Greg Neely, I'm from the University of Sydney. 
[Image shows Greg pointing to the bottom of the screen in the background and text can be seen: A University of Sydney Spinout, Chronic Pain Australia 2024]
I'm with Enhanced Analgesics and we've made a new painkiller that we're trying to develop through for human use. So as you heard, painkillers don't work for most people, that’s especially the case for chronic pain. So with chronic neuropathic pain, 70% of patients, there's no drugs that work, so that leaves them in chronic untreated pain. 
[Camera zooms out as Greg continues talking to the audience from centre stage, and a new slide shows a close rear view of a hand on a neck, and text appears: Untreated Pain Destroys Lives, 70% unable to work, 80% experience mental health issues, 80% of heroin users start with prescription opioids, Chronic Pain Australia 2024]
And untreated pain basically destroys people's lives. So 70% of people that have chronic pain are unable to work, 80% of people have significant mental health issues. And then this is brutal but if you look at current heroin users, 80% of them started with prescription opiates. 
[The camera zooms in to a medium view of Greg as he continues talking from centre stage]
So it's like, it's a major problem and, and we and everyone, lots of people around the world are trying to deal with that. So the way we dealt with it is that we we kind of started from first principles with new genomic technology. We took animals that were in, in pain and then we took animals where their pain was treated and we compared those two using basically single cell sequencing and spatial transcriptomics, a bunch of genomic technologies that are recently available. 
[Camera zooms out as Greg continues talking to the audience, and a new slide shows two mice, one in pain and one with treated pain with downward arrows and text heading and text appears: What controls pain? Mouse in pain, Mouse with treated pain, We found what controls pain]
So it gives us kind of like a picture of everything that's happening in the animal and, and what, what goes with treated pain versus untreated pain. 
[Image continues to show Greg talking from centre stage, and a new slide shows a diagram showing EA1 being put in the nose on the human head on the right, and text appears on the left: EA1, a new non-opiate pain killer, - EA1 mRNA codes for a strong painkiller, - Creates a pain killer “pump” in the nose, - Provides long lasting pain relief, - No obvious side effects]
So using that information, then we saw a bunch of things that we could use therapeutically and one of them stood out so we developed it further. 
[The camera zooms in to a medium view of Greg as he continues talking from centre stage]
And it's basically a human kind of master pain regulator that we took and put into an mRNA and it's like a synthetic version of a human gene. We put it into an mRNA and then it's wrapped in a lipid nanoparticle. So that's basically the same thing as a Covid 19 vaccine, except you're instead of getting injected into your arm, we put it into the nose. And then once it's in the nose, it's produced by the nasal epithelium and it can diffuse into, into your brain basically. 
[Camera zooms out as Greg continues talking from centre stage, and a new slide shows pathways of yellow for pain and blue for less pain in two human silhouettes, and text appears: EA1 Activates our brain’s pathways that block pain, Pain, EA1, Less Pain]
Once it gets to your brain, what it does is it kind of triggers your brain's descending inhibition pathway so it basically shuts down our natural ability to control pain, sorry, it actually activates our natural ability to control pain and shuts down pain. 
[Images move through to show Greg talking from centre stage, and then a medium view of Greg talking, and a new slide shows a circle with three different billions of dollars used, and text appears: $80B Global Pain Market, $40B Opiod Market, $2B Aiming for 5% Market Capture, Pain therapeutics market is predicted to grow from 78 billion to 115 billion(2035). There is a global effort to replace opioids with non-addictive alternatives]
So it's really cool, we got a proof of principle, and we have an agent that we think we can develop an asset we think we can develop. So looking at the pain market, it's massive. It's $80 billion a year, $40 billion of that is opiates. And then basically there's a massive move right now from US government, EU, Australia to cut down on opiate use. But we didn't develop for the last 20 years, we didn't develop lots of new non-opiate drugs so there's a gap. So we have now a non-opiate drug that we think can help fill that gap, we’d like to capture 5% of that market. 
[The camera zooms out as Greg continues talking to the audience from centre stage, and a new slide shows a Commercialization Plan]
So when we started with ON Accelerate we had this basic science data and we had that it worked in animals, but we we had no idea really how to take it through and get towards humans. 
[The camera zooms in to a medium view of Greg as he continues talking from centre stage]
And so this course has been awesome over the last six months, we took just our asset and we developed it into a business plan and then now we're I think we're well on our way. We've got this patent now, we’ve just hired a regulatory consultant and then we're going to do a capital raise and then we can we have tons of animal data already, but we have to do a little more safety studies and then we can do a phase one clinical trial in Australia. 
So this is the Enhanced Analgesics team. Together we've got 30 years of experience with pain research. And so what we're looking for is if anyone out there has like tons of money, come talk to us at our booth. 
[The camera zooms out as Greg continues talking to the audience from centre stage, and a new slide shows four male profile photos of the team in between text: Join us and help make the future of pain relief a reality, Prof. Greg Neely, CEO, Dr Lipin Loo, CTO, Dr Adam Cole , COO, Dr. Julius Juarez, CCO, -30+ years experience in pain research, - Globally unique expertise in mRNA therapies for neurological diseases]
If you've developed drugs or you're interested in our technology, please also come talk to us. And if you have tons of money and you're interested in our technology, for sure, come say hi. Thanks.
[Applause can be heard and music plays and the image shows the audience applauding Greg as he exits left and walks in front of the stage, and a new slide appears with the University of Sydney logo]
 [Music plays as the audience is applauding Greg as he exits the stage to the left and walks across the room to the right, and a new slide shows an orange screen with the University of Sydney logo]
[Image changes to show an animation of a group of females, and then the image changes to show a set of balance scales moving up and down as various symbols fall into the dishes, and text appears: Over 1.6 million women each year, Surgery, Wait and See]
Narrator:  Every year, 1.6 million women suspected of having ovarian cancer are given a choice - undergo surgery for further diagnosis, which turns out to be unnecessary in up to 80% of cases and often results in surgical complications and permanent loss of fertility, or wait and see, which can result in aggressive treatment, high costs and poor survival rates. 
[Animation image changes to show a red speckled screen with text: ProSeek Bio]
But we're developing a revolutionary new option a highly accurate, non-invasive test to help doctors determine if surgery is actually required. 
[Animation image changes to show a split screen of Biomarker identities chart on the left and a sample of the biomarkers in an image of ovarian cancer on the right]
Our pioneering technology targets a set of blood glycoproteins to identify biomarkers for ovarian cancer. 
[Animation image changes to show a hand selecting a test from a ProSeek Bio box, then the camera pans left to a mass spectrometer holding multiple samples]
A regular blood test is taken and our test kit is used to measure the biomarkers on a mass spectrometer in a pathology lab. 
[Animation image changes to show a ‘No Cancer Biomarker Patterns Detected’ booklet  in front of a female, and then the image changes to show four females with heading text above them: and text appears: Earlier Diagnosis, Less Surgeries, Lower costs, More lives saved]
Our algorithm interprets the results and provides doctors with powerful insights to inform their recommendations, meaning earlier diagnosis, less surgeries, lower costs and most importantly, more lives saved. 
[Animation image changes to show the ProSeek Bio log, and text appears: Knowledge to diagnostics, www.proseekbio.com]
We're on a mission to reduce ovarian cancer fatalities. Join us.
[Music plays and the image changes to show Michelle Hill talking to the audience from centre stage, and a new slide showing a female sitting on a jetty with an inset Smartphone showing balance scales] 
[The camera zooms in to a medium view of Michelle as she continues talking from centre stage, and text appears: Michelle Hill, PhD, ProSeek Bio]
Michelle Hill: Hi everyone. My name is Michelle Hill and I founded ProSeek Bio to translate my biomarker discoveries into diagnostics so that women have a real choice before ovarian cancer surgery. It takes on average eight months for ovarian cancer diagnosis. 
[The camera zooms out as Michelle continues talking to the audience from centre stage, and a new slide shows three females looking at the camera on the right, and text appears on the left: Ovarian Cancer]
As a result, most cases are too late for effective treatment. Every day, three women in Australia die from ovarian cancer, making it the biggest killer of women, female cancers in the world globally with rising incidence. 
[The camera zooms in to a medium view of Michelle as she continues talking from centre stage]
Scientists have been looking for effective diagnostic biomarkers in blood for decades but have failed to make a real difference. That's where ProSeek Bio comes in. 
My journey in biomarker research actually began with my grandfather's passing from oesophageal cancer. 
[The camera zooms out as Michelle continues talking to the audience from centre stage, and a new slide shows the Proteomics International logo on the right, and text appears: 
It took 13 years, but happily, we were successful in out-licensing our world first oesophageal cancer blood biomarkers to a company for commercialisation. 
[Images move through to show Michelle talking to the audience from centre stage, a close view of Michelle talking, and a new slide showing a timeline of the Foundation’s journey, and text appears: The journey so far, Biomarker Platform Development 2009 – 2017, Glycoprotein biomarker platform, Proof of concept, Ovarian Biomarker Discovery, 2017 – 2022, Clinical questions, Candidate biomarkers]
As a woman scientist, I was thrilled to be funded by Ovarian Cancer Research Foundation to find biomarkers for ovarian cancer to solve this big problem. Our very promising results were published and our international gynaecologist collaborator, who had 30 years ovarian cancer detection research experience, said to me, I'd love to continue this collaboration with you, but which entity are we working with? 
[Camera zooms out as Michelle continues talking to the audience from centre stage, and the image changes to show a medium view of Michelle talking, and new text can be seen on the timeline slide: Researcher in the Industry Fellowship, 2022 – 2023, Market identification, Value proposition, Startup ideation, Partner exploration, ON Accelerate, 2024, Quality & regulatory strategy, Go to market strategy, Governance, Financial & growth strategy]
As it turns out, I was doing my REDI fellowship and getting startup ideas and that's where ProSeek was born. Through the amazing ON Accelerate program my amazing team have been well equipped in the last six months with all the tools that we need for the road ahead. We now have a roadmap to help all the women in the world through in vitro diagnostics development, partnering with pathology labs and clinical trials to international expansion. ProSeek Bio is transforming women's health with next generation diagnostics tests. We'd love for you to join us on this journey. 
[The camera zooms out as Michelle continues talking from centre stage, and a new slide shows  three smiling females on the right and a QR code above the ProSeek Bio logo on the left, and text appears: Come on the journey with us! www.proseekbio.com]     
Please connect with us today. Thank you very much.
[Music plays as the audience applauds Michelle exiting the stage to the left, and walking across to the right, and a new slide shows a white screen with the QIMR Berghofer Medical Research Institute logo] 
[Image changes to show an animation image of an aerial view of power lines and “-3%” appears in circles along the power line, and then the animation image changes to show a coal power station]
Narrator: Every year, electrical grids lose 3% of all generated energy due to magnetic losses. That's equivalent to an entire coal power station wasted annually in Australia alone.
[Animation image changes to show a person’s head, machinery and renewable energy symbols, and text appears above and below the symbols: Increased Costs for, Consumers, Industry, Renewable Energy]
These losses reduce efficiency and increase costs, impacting consumers, industries and renewable energy generators. 
[Animation image changes to show a power transformer on the left and an electric motor on the right]
Replacing conventional cores with amorphous metallic foils provides transformers and motors with breakthrough efficiency and higher performance. 
[Music plays as animation image changes to show a close view of a transformer foil overheating on the left, and text appears on the right: 1 million degrees per second cooling]
But these foils have been difficult to produce, until now. 
[Animation image changes to show hardware innovation symbol on the left and an AI machine learning symbol on the right, and then the animation image changes to show a blue screen with text: Amorfoil]
By combining hardware innovation with the power of AI, we've developed an advanced manufacturing process to produce these advanced foils cost effectively at scale. 
[Animation images move through to show a four way split screen of types of renewable energy, and then symbols of a robot head, a checklist, a clock and a rubbish bin, and text appears: Machine Learning, High-Quality, Reliable Production, Minimised Waste] 
From transformers on telegraph poles to solar and wind farms, EVs and charging stations, we’re unlocking domestic production capabilities and increasing export opportunities, saving billions in energy costs and cutting carbon emissions. 
[Animation image changes to show a blue screen with text: Amorfoil, To learn more, contact daniel.liang@csiro.au]
The future of energy efficiency is here. Join us.
[Image changes to show Roshan Dodanwela walking on stage from the right, and then he begins talking to the audience from centre stage and a new slide appears showing text: Amorfoil, To Learn More, Contact DANIEL.LIANG@CSIRO.AU]
Roshan Dodanwela: Good afternoon. 
[Image continues to show Roshan talking to the audience from centre stage, and a new slide shows a blue slide with white streaks, and text appears: High Energy Efficiency and Low Production Cost, Electrical Amorphous Steel Foils]
My name is Roshan and I represent the Amorfoil team. 
[The camera zooms in and then out on Roshan as he continues talking from centre stage, and a new slide shows electricity moving from the power plant, to a house, and text appears: Roshan Dodanwela, An inefficient electricity grid]
As seen in the video the national grids suffer a 3% loss between the power generation station and the end user. And the reason for this loss is shown here, the electrical transformers. 
[The camera zooms in to a medium view of Roshan as he continues talking from centre stage]
Electrical transformers are made from a steel that's inefficient and the technology hasn't changed in over 100 years. So as our grid ages and as transformers age, that 3% loss is only going to increase, which means higher electricity prices. That’s where Amorfoil have come up with this great solution, a new type of electrical steel that can bring that 3% loss down to 1%. And that 1% is a massive amount of energy savings, which translates to cheaper electricity prices. Also, because transformers are an essential part of any grid they're worth, they are $1 trillion global market. 
[The camera zooms out as Roshan continues talking from centre stage, and a new slide shows a car battery on the left and various machines requiring electrical motors on the right, and text appears: For use in electric motors]
Turns out Amorfoil has had another win because our type of special steels are in high demand in electrical motors. 
[The camera zooms in to a medium view of Roshan as he continues talking from centre stage]
Electrical motors are very versatile and found across many industries from domestic refrigerators, washing machines, blenders to transport, aerospace and increasingly in electric vehicles and drones. Electric motors with this special type of steel become very efficient, so they become smaller, which means their cost reduces and the amount of energy they use reduces so the power bill reduces. Our Amorfoil team is working with industry leading motor manufacturers to customise our steel for for the electric motor market. 
[Camera zooms out as Roshan continues talking from centre stage, and a new slide shows males working in a steel factory on the left and a hand holding a smartphone on the right, and text appears: AmorFoil’s technology advantage, Specialised electrical steel foil is difficult to produce, AmorFoil’s technology can cut material loss by up to 50%] 
So our steels, the special steels are very difficult to produce. There is a very high defect rate and there's only a handful of companies globally who control the market and their order books are full for the next five years. 
[The camera zooms in to a medium view of Roshan as he continues talking from centre stage]
So our advantage is that we have come up with an AI enabled process that cuts that wastage down by 50%, and we have a faster path to market. We have a three stage plan. The first stage is to go from our pilot prototype to produce foils that are required to put in transformers and motors. So for this stage, we are seeking up to $3.85 million from investors and government grants and this will be matched by CSIRO and our industry partners in kind. 
[The camera zooms out as Roshan continues talking from centre stage, and a new slide shows the three step process in years to produce the product, and text appears: A 3-stage pathway to market, 2025-2057, Scale-up pilot production facility $3.85mn investment, 2026-2028, Prototyping and field-demonstrating medium-voltage transformers, inverters and motors, 2027, The AmorFoil start-up company]
So once we have the, once we have the foils we will work with our leading industry partners and build transformers and motors and put them on field trials. And the next stage is for Amorfoil to start up. 
[Images move through to show views of Roshan talking from centre stage, and two new slides move through showing profile photos and contact details of the team, and then a title slide: Seeking to connect with investors, industrial partners and research collaborators]
So we have a wonderful team of metallurgists, scientists, engineers, commercialisation, IP people and we are all looking forward to having a chat with you and joining us on our journey forward. 
[Applause can be heard as The camera zooms out as Roshan continues talking to the audience from centre stage]
Thank you very much. 
[Music plays as the audience applauds Roshan exiting the stage to the left, walking across the room to the right, a new slide shows a blue screen with the CSIRO logo]
[Image changes to show an animation of grey ceramic on the left and grey tiles on the right, then two orange balls appear smashing the ceramic side and bending the tiled side, and text appears: Thermal Insulation, Corrosion Resistant, High Hardness]
Narrator: Imagine if we could create a material that had all the unique properties of ceramics, but instead of breaking, it could bend. 
[Music plays as animation image changes to show a grey screen with the 3D Ceraflex logo]
At 3DCeraflex we've made it a reality. 
[Camera zooms out to show an aerial view of the 3D printer printing, and the camera pans down to show the front of the printer showing printed words inside: STRONG FLEXIBLE FIREPROOF]
Our proprietary 3D printing technology prints ultra thin, complex ceramic structures that can flex, absorb stress and withstand extreme temperatures. 
[Animation image changes to show a battery on the left and ticks appear alongside the text on the right: Faster Charging, Longer Life, No Fires]
When used in batteries, that means faster charging, longer life and no fires, solving energy storage's three biggest challenges
[Animation image changes to show a car driving along a city street past buildings, charging stations, houses and skyscrapers with power symbols above, and the camera pans into a house window]
 - making renewable energy storage more reliable, electric vehicles safer and consumer electronics longer lasting. 
[Animation image changes to show a hand holding a smartphone while another hand operates a screen with data graphs]
But energy storage is just the beginning. 
[Animation images move through to show a rocket blasting off, plane jets firing, a knee implant, and then a necklace on the left, while text appears sequentially on the right: Aerospace, Defence, Medical Implants, Luxury Goods]
We can develop ceramics with specific properties, enabling innovation in aerospace, defence, medical implants, luxury goods and beyond. 
[Animation image changes to show an underwater view of the sea floor showing seaweed and coral reefs]
We're even using it to revolutionise coral reef restoration. 
[Animation image changes to show a grey screen with the 3D Ceraflex logo, and text appears: To learn more, contact elsa.antunes1@jcu.edu.au]
The possibilities are endless. We're bending the rules of ceramics and reshaping the future. Join us.
[Image changes to show Elsa Antunes talking to the audience from centre stage below a new slide of wavy material on the right and the 3DCeraflex logo below text on the left: Bendable ceramic materials designed for use in extreme environments]
Elsa Antunes: Hello everyone. 
[The camera zooms in to a medium view of Elsa as she continues talking from centre stage, and text appears: Elsa Antunes, 3DCeraflex]
My name is Elsa Antunes and I am the CEO and co-founder of 3D Ceraflex. Today I'm here to talk about ceramics. Not ceramics that we are using for coffee cups but instead I'm going to talk about technical ceramics. Imagine if the strongest material in the world can flex. In fact, 3D Ceraflex did it. 
[The camera zooms out as Elsa continues talking to the audience from centre stage, and a new slide shows flame blasting ceramic material on the right and a check list appears with text on the left: Ceramics today, -Excellent thermal and mechanical properties, -High melting point, -Hard and brittle, Complex shapes difficult to produce, -Creating specific properties is challenging]
Ceramics are amazing materials, they have great thermal and mechanical properties, they have high melting point but they have a few problems. They are hard and brittle. 
[The camera zooms in to a medium view of Elsa as she continues talking from centre stage]
It is difficult to manufacture them into complex shapes. But we solve all of these problems. Yes, we solve these problems. We are able to create unique engineering solutions. We are able to make them flexible and further we are able to make complex shapes. As we have seen in our video, we have endless opportunities.
[The camera zooms out as Elsa continues talking to the audience from centre stage, a new slide shows images of a part of a rocket, a building, surgery being performed, and gold watch, and text appears: Creating endless opportunities, Aerospace and Defence, Energy Storage, Biomedical Implants, Luxury Goods]
In the aerospace field and defence, we can create these materials for extreme environments. For the energy storage we can make batteries safe. 
[The camera zooms in to a medium view of Elsa as she continues talking from centre stage]
And on the other side for the biomedical field, we can tailor made biomedical implants for you and we know that we can improve patients recovery. And further, even we can use these for luxury goods, we can create unique designs and personalise them just for you, like I did today for me. So we have a significant traction. 
[The camera zooms out as Elsa continues talking to the audience from centre stage, a new slide shows  a 3D printer printing on the right, and text appears on the left: In fact, we already have the significant traction, -Lockhead Martin pilot study, -Medical device pilot, -Other pilot studies under discussion, -Staate-of-the-art Lab scale facility]
So we secure to this program two pilot studies, one in the defence area with Lockheed Martin Australia and the other one in the biomedical field with the US partner. 
[The camera zooms in to a medium view of Elsa as she continues talking from centre stage]
At the moment we are as well doing or having more discussions and we are just about to finalise one more pilot study in the luxury goods field where we are going to make ceramic watches. So the next steps is in fact to convert all of these partnerships into customers, because they will allow us then to create and raise seed capital to manufacture, to scale up the manufacturing of our technology. Why us? 
[The camera zooms out as Elsa continues talking to the audience from centre stage, and a new slide shows profile photos of the three team members, and text appears: So why us?, Elsa Antunes, CEO, Matthew Drane, CTO, Tejas Koushik, COO]
Because first we are really amazing and second, because we are dreamers, we are innovators and we have a unique set of skills that will allow us to take this technology further. 
[Image continues to show Elsa talking to the audience from centre stage, and a new slide shows a piece of machinery in operation and a male pumping up a balloon with a dollar sign, and text appears: What we’re looking for, Partners and Customers, Funding Interest]
And today I'm not asking too much. 
[The camera zooms in to a medium view of Elsa as she continues talking from centre stage]
I would like to partner with you, find the new potential customers and I'm keen, or we are keen, to discuss potential funding opportunities. 
[The camera zooms out as Elsa continues talking to the audience from centre stage, and a new slide shows  a white slide with the 3D Ceraflex logo above text: Let’s create the future of advance manufacturing right here in Australia, Join us on our 3DCeraflex journey, get in touch, elsa.antunes@jcu.edu.au, 0498 656 948]
So please join us today and let's shape the future of advanced manufacturing right here in Australia. 
[Applause can be heard the image continues to  show Elsa talking to the audience from centre stage]
Thank you so much. 
[Music plays as the audience applauds Elsa exiting the stage to the left, and then walking across the room to the right, and a new slide shows a blue screen with James Cook University Australia logo]
[Image changes to show an animation of an infected bleeding wound]
Narrator: Small wounds can turn into serious medical threats if they get infected. 
[Animation image shows the wound being covered with a band-aid, which then morphs into an antibiotics tablet]
Today, wounds are treated with dressings and we rely on antibiotics to treat infections. 
[Animation image changes to show the tablet in a white circle with a resistant bacteria and other cells, and then the circle spreads and divides into two circles, and then  four circles]
But as bacteria evolve and antibiotic resistance spreads, we need a smarter way to fight infection. 
[Animation image changes to show the TopiCure logo, and then the camera zooms out to show the logo on a tube applying cream from the left across the screen]
Introducing TopiCure, a next generation gel for topical delivery of antimicrobial agents. 
[Animation image changes to show a side view of the cream spread across a wound and then sinking into the wound]
Think of it as a smarter, longer lasting antiseptic that actually gets where it needs to go. 
[Animation image changes to show sequentially in a green circle a teardrop , bacteria and then a hospital symbols above corresponding text: Hydrates Wounds, Prevents Infection, Heals Faster]
Unlike traditional creams that dry out or get wiped away, our gel stays active, hydrating wounds, preventing infections and promoting faster healing. 
[Animation image changes to show a tube applying cream from left to right around an infected cell, below a hospital, and then under a white circle with a downward pointing arrow]
The result? Reduced infection rates. Reduced hospital stays. Reduced treatment costs. 
[Animation image changes to show a new slide with the TopiCure logo above text: www.topicure.org]
We're stopping infections before they start. Join us.
[Image changes to show Dr Saffron Bryant walking on stage, and the camera zooms in on Saffron talking, and a new slide shows a young male’s scraped knee on the right, and text appears on the left: Delivering Medicine Topically]
Dr Saffron Bryant: Welcome to TopiCure. Have you ever tried to give a pill to an injured cat? What about make a sick child take their medicine when they're really not feeling well? Antibiotics are vital to health, and yet they're typically delivered as either pills or injections. And this presents serious problems for carers of animals, but also people supporting vulnerable populations like children but also the elderly or those with special needs. 
[The camera zooms out as Saffron continues talking to the audience from centre stage, and a new slide shows a green screen with text: Have you ever tried to give a pill to a cat?]
That's why at TopiCure we have developed an antimicrobial gel that can be applied directly to the skin, which means no more needles and no more pills. 
[Image continues to show Saffron talking to the audience from centre stage, and the camera zooms in on Saffron talking, and the slide shows new text: What about medicine to a really sick child?]
Now, you might already be familiar with normal hydrogels, but our gels so-called eutectogels are better in every way. So firstly, they don't contain any water, which means they never dry out as shown in the video, hopefully, video. And they're also stable under ambient conditions for a long period of time. 
[The camera zooms out as Saffron continues talking to the audience from centre stage, and a new slide shows a glass of clear liquid on the right and a checklist below a text heading on the left: Our eutectogels are superior to existing hydrogels, -They Don’t Evaporate, -They’re Stable for Weeks, -They’re Tunable, -Sustained Release, Hydrogel Eutectogel] 
They're also tunable, which means that they can be loaded with any sort of cargo, including drugs that are not soluble in water, which provides long term stable release. 
So the topical pharmaceutical market is massive, with a compound annual growth rate nearing 10%. 
[The camera zooms in to a medium view of Saffron as she continues talking from centre stage]
Our conservative estimates suggest that our serviceable obtainable market would be about $200 million per year. We have already won $3.5 million in undiluted funding from an international consortium grant and also an Australian Economic Accelerator grant. This gives us enough funding to take us through small animal trials. 
[The camera zooms out as Saffron continues talking to the audience from centre stage, and a new slide shows a timeline of the company’s journey from clinical trial  in 2022 to market in 2026]
We've also got funding to engage a regulatory consultant who will help us devise our clinical trial package and our pathway to market. 
[Images move through to show Saffron on stage talking and a medium view of Saffron, and a new slide shows the PolyNovo, BiomeMega, DentaLife and Animal Health logos, and text appears: We’re in good Company, We are already in talks with multiple companies who are interested in our technology]
Now, in addition to that undiluted funding, we're in discussion with multiple industries who are interested in using our gels for their applications. The funding that we already have in the small animal trials will take TopiCure to its next value inflection point. But we want you to join us on that journey. So we're looking for clinicians to partner with us. 
[The camera zooms out as Saffron continues talking to the audience from centre stage, and a new slide shows cream being applied to a deep wound on the right, and text appears on the left: People already want our gels, “Longer term option would be fantastic.”, “Better handling of acute treatment could prevent chronic wounds, “Current treatments are ineffective and barely work”]
We're looking for pharmaceutical companies who have a drug that they want to deliver topically. We’re looking for investors who want to get in early. And we're looking for advisers to guide us on this journey. 
[Image continues to show view of Saffron talking to the audience, and slides flick through showing symbols of clinicians, a pill bottle and money bag, and then a QR code, the TopiCure logo and text: Be part of something big, Clinicians, Pharmaceutical Companies, Investors Advisory Board, Get in touch, info@topicure.org]
So please come talk to the team myself, Aaron and Shreehari over at our booth because at TopiCure we're delivering medicine topically tailored for cheaper, faster and safer results. Thank you.
[Applause can be heard and music plays as the audience applauds Saffron exiting the stage, and then walking across the room to the right, a new slide shows a white screen with the RMIT University logo] 
[Image changes to show a close view of a child’s eyes and nose as the camera pans in closer to the child’s right eye]
Narrator: For some children, life begins with an unimaginable struggle, severe epilepsy caused by a genetic mutation that alters brain function and causes seizures. 
[Images move through to show a very close view of the eye as seen under a microscope during a seizure]
These children suffer over 50 seizures a day. Existing treatments don't work. 
[Image changes to show a medium view of a child looking at the camera as the camera pans in to the child’s face and the child’s eyes can be seen flicking open and shut]
Most won't live to their 10th birthday. The need for a breakthrough has never been greater. 
[Image changes to show a yellow screen, and text appears: epiblox]
At EpiBlox we've identified a drug that shows promise of revolutionising epilepsy treatment. 
[Music plays as animation image changes to show a white droplet dropping into a measuring cup of white liquid, then image morphs into a white circle and splits in half showing coloured squares]
Taken as a syrup or pill, the drug directly targets the cause of the seizures in the brain. 
[Music plays as the animation image changes to show triangles moving down over the squares, and then a circle reverberates from a single square making a pinging sound, and text appears: The best bit?]
The best bit. 
[Animation image moves through to show a molecule rotating left, and then a tick alongside text “Proven safety record”, and then a road moving up the screen]
We're using a well-studied molecule that is already proven to be safe in children, allowing us to accelerate our path to clinical trials. 
[Music plays as animation image shows the camera zooming along the road, and then the image changes to show a smiling baby looking at the camera, and two girls smiling at the camera]
A future without seizures means these children can develop, learn and live longer, healthier lives. 
[Image changes to show a male smiling at a baby held by a smiling female, and then looking up smiling at the camera]
Families regain hope. 
[Image changes to show a boy laughing with a red clown’s nose over his face, and then the image changes to show a stethoscope on a table beside a hand writing on documents]
Hospitals can finally provide effective treatment, and governments reduce healthcare costs. 
[Image changes to show a yellow screen, and text appears: epiblox, www.epiblox.com]
Help us bring this life changing treatment to children in need.
[Image changes to show Dr Michael Ricos walking on stage, and the camera zooms in on Michael talking from centre stage, and a new slide shows the epiblox logo, and text appears: Dr Michael Ricos, EpiBlox]
Dr Michael Ricos: When a child is born, there is tremendous excitement and dreams about their future. For children with KCNT1 epilepsy, those dreams are all too soon stolen by epileptic seizures. They lose the ability to sit up or even hold a rattle. I'm Dr. Michael Ricos and I'm from EpiBlox and I'd like to introduce you to Ember. Ember has KCNT1 epilepsy. 
[The camera zooms out as Michael continues talking to the audience from centre stage, and a new slide shows a photo of Ember in a motorised chair, and text appears on the right: Ember, Age 4, Shared with permission of family]
Life for children like Ember and her family will be an incredibly difficult struggle. 
[Image continues to show Michael talking to the audience from centre stage, and a new slide shows a  multitude of different pills, and text appears: No medications work for KCNT1 epilepsy., “If we could recover 10% of our child’s cognitive ability it would be a huge leap for our child and for us.”, -Parent of child with KCNT1 epilepsy]
And what's worse is that no medications work for this type of epilepsy, and many children won't celebrate their 10th birthday. Parents are desperate because the clock is ticking. 
[The camera zooms in to a medium view of Michael as he continues talking from centre stage] 
At EpiBlox, we're providing hope for children like Ember and their families. We searched the DNA and discovered the KCNT1 gene was the cause of their epilepsy. We determined the KCNT1 gene caused a hyperactive electrical pump in the brain of these kids. Knowing that was the cause of the seizures gave us a way to tackle the disease. 
[The camera zooms out as Michael continues talking to the audience from centre stage, and a new slide shows DNA strands, a brain firing, and a drug’s chemical structure, and text appears: Unlocking hope, Discovered the gene of KCNT1 Epilepsy, Worked out the disease mechanism, Identified a drug to stop seizures]
If we could block this hyperactive electrical pump in their brains, perhaps we could stop the seizures and save these children. We searched and found a molecule that could block this electrical pump, and it reduced seizures in our preclinical animal model and that was the game changer. 
[The camera zooms in to a medium view of Michael as he continues talking from centre stage] 
We know the drug is safe, it was previously used in Europe as an anti-inflammatory. We've been able to license that historical data to get us to market cheaper and quicker than others. And the FDA has recognised us with incentives for rare disease drug development that will guarantee a return on investment. 
[The camera zooms out as Michael continues talking to the audience, and a new slide shows a small circle with two families inside, and a large circle with multiple families inside, and text appears: Lives Transformed, KCNT1 Epilepsy, Other Epilepsies] 
We will impact the lives of thousands of children like Ember and their families with KCNT1 epilepsy, and we believe we can expand our drugs use to treat another couple of rare epilepsies to further increase our impact. 
[Image continues to show Michael talking to the audience, and the camera zooms in on Michael, and a new slide shows a large circle on the right and a small circle on the left, and text appears: Market potential (USD), KCNT1 Epilepsy $200M, Other Epilepsies 1.1B]
We predict annual sales of US $200 million just to treat children like Ember with KCNT1 epilepsy. And if we can expand our use to two other epilepsies, we can push sales well in excess of $1 billion and maybe beyond. We've assembled a global multidisciplinary team with expertise in genetics, neuroscience, pharmacology and medicinal chemistry. And we've got a team of regulatory and FDA specialists standing by to join us. 
[The camera zooms out as Michael continues talking to the audience from centre stage, and a new slide shows a bar graph showing dollar amounts for the path to market, and text appears: A defined fast-track path to market and ROI] 
We've mapped a clear path to market with milestones and funding required to reach them. And once we receive regulatory approval, that unlocks the rare paediatric disease designation incentive from the USFDA worth $150 million. 
[Images move through to show views of Michael talking, and a new slide shows a photo of Ember on the right and photos of team members above a QR code on the left, and text appears: Join us to bring Ember and other children hope, Get in touch with us hello@epiblox.com, Prof Leanne Dibbens, Dr Michael Ricos, Dr Rashid Hussain, DrZeeshan Shaukat, Dr Pradeep, Learn more at epiblox.com]
If you've been moved by Ember's story and the plight of children like her, and you would like to know more about EpiBlox mission to bring this drug to those children that need it, come and join us and talk to us. We're here at showcase. 
[Applause can be heard as The camera zooms out as Michael continues talking to the audience from centre stage]
Thank you. 
[Music plays as the audience applauds Michael exiting the stage to the left, and then walking across the room to the right, a new slide shows a white screen with the University of South Australia logo]
[Image changes to show an animation of a molecule slowly rotating right, and text appears: What is Ammonia?]
Narrator: What is ammonia? It's an inorganic chemical compound of nitrogen and hydrogen that has become the foundation of modern agriculture.
[Animation images move through to show a molecule and seeds on the left and photos of a harvester and farmer on the right of the Earth, and then coal power stations emitting CO₂, and text appears: $200B Industry, Fertiliser]
It's the backbone of global food production but it's also one of the world's biggest polluters. 
[Animation image changes to show the emissions forming a cloud representing 500m tonnes of CO₂ emitted]
Every year, making ammonia releases 500 million tons of carbon dioxide into the atmosphere. That's more than the entire aviation industry combined. 
[Animation image shows people multiplying on the left as the emission cloud tonnage continues to escalate on the right]
And as our population grows, so does the problem. 
[Animation image changes to show a molecule being compressed between two dark shapes, “Fossil Fue Prices” on the left and “Unsustainable Emissions” on the right]
So the industry currently has an issue. It's caught between rising fossil fuel prices and unsustainable emissions. 
[Animation image changes to show a grey screen, and text appears: Facet, Amtech]
But we've made a breakthrough, a revolutionary new way to produce ammonia. 
[Animation image changes to show three encircled photos of clouds, water and the sun, and text appears: Air, Water, Renewable heat]
Instead of burning gas, we use air, water and renewable heat. No fossil fuels, no emissions. 
[Animation image changes to show a two graphs of prices going down, over a bag of Fertiliser Sulphate of Ammonia on the left and over vegetables on the right]
Farmers get affordable fertilisers and food becomes cheaper everywhere. 
[Camera zooms out to show the previous images within a circle diagram on the left, and symbols of a train, a cargo ship and a power plant appearing inside a larger circle, and text appears: A Clean Energy Future]
But that's just the beginning. Ammonia can also be used to power the clean energy revolution, replacing diesel, natural gas and coal. 
[Animation image changes to show a molecule slowly rotating on the right beside text: Facet Amtech, www.FacetAmtech.com]
We're transforming global ammonia production. Join us.
[Image changes to show James Bradley walking on stage, and the camera zooms in on James talking, and a new slide shows a molecule on the right and text appears: Fuel of the future, Unlocking the green energy revolution with ammonia, James Bradley, Facet Amtech]
James Bradley: G'day. My name is James Bradley and I'm a co-founder of Facet Amtech and we're rethinking how the world makes ammonia. For over 100 years, we've been completely stuck making ammonia at high temperature and pressure and using a whole pile of energy and making energy in the Goldilocks zone here has been seemingly impossible until now. 
[The camera zooms out as James continues talking to the audience from centre stage, and a new slide shows a pressure and temperature graph of comparison for ammonia production and text appears: Ammonia Production: Facet Amtech, Fe-based, High-Performance catalysts]
At Facet Amtech we can make ammonia in these conditions but that's not all. We can also do it in a single step using just air and steam. So what does this mean, making ammonia from steam? 
[The camera zooms in to a medium view of James as he continues talking from centre stage]
Well, it means we can make it cheaper and we can also help decarbonise about 40% of industry. Marine shipping is one example that's already working hard to use ammonia as a green fuel - and I've done that wrong - anyway, as a green fuel. And to do that we're going to need approximately 100 million tons of additional ammonia produced. 
[The camera zooms out as James continues talking from centre stage, and a new slide shows an arrowed line gradually going upwards showing the plans for Ammonia growth, and text appears: Committed plans for clean Ammonia, 2024, $200B, Current Ammonia Production, 2030, $223B, New Clean Ammonia Production, 2030+, $418B, New Clean Ammonia Plants in Progress for Construction post-2030] 
This early drive by marine shipping means that there's already new green ammonia plants committed up until and beyond 2030. And with some people saying that we're going to need approximately six times more ammonia than we currently make by 2050. 
[Image continues to show James talking to the audience from centre stage, and the camera zooms in on James, and a new slide shows a model column diagram of the growth plans, and text appears:  Our model for success, Multiple revenue streams, from licence fees for plant IP, ongoing royalties on production and income for catalyst supply]
We're working in an industry where licenses and IP deals are kind of normal and so that means that we can partner with an already existing industry to rapidly deploy our technology. So the opportunity is just huge. We have a team of engineers and material scientists and we love kind of making cool things, to be honest. And so when the opportunity came for us to upturn an entire industry, we jumped on it. 
[The camera zooms out as James continues talking from centre stage, and a new slide shows profile photos of the three team members beside four partner’s logos listed on the right, and text appears: Meet our team, Dr Peter Richardson, CEO, James Bradley, CPO, Dr Jessica Merz, Research Engineer]
We've been really busy during the program over the last six months. 
[The camera zooms in to a medium view of James as he continues talking from centre stage, and text appears behind him: info@FacetAmtech.com]
We've finalised a fantastic deal with the University of Newcastle, lodged our first patent, scaled our catalyst and have spoken right across the industry to a whole bunch of people who are excited to see what we can do next. And we've also raised funding from Main Sequence Ventures and UniSeed, including a second tranche of funding unlocked just this Monday. 
So now we've got a whole pile of really hard work to do to prove the technology to the next steps to look at a fundraise towards the end of this year so that we can pilot for next year. So if you'd like to join us rethinking how the world uses ammonia, come and talk to myself or Jessica after this. 
[The camera zooms out as James continues talking from centre stage, and a new slide shows a molecule on the right, and text appears on the left: Seed raise 2nd half 2025, Pilot Plant 2026, info@FacetAmtech.com]
Thank you so much. 
[Applause can be heard and music plays as the audience applauds James exiting the stage to the left, and walking across the room to the right, and a new slide shows a black screen with the University of Newcastle Australia logo]
[Image changes to show an animation image of people’s head and shoulders and the camera zooms out showing the crowd of people forming into a 20% symbol, and text appears: 1 Million People, Dissatisfied]
Narrator:  Every year over a million people undergo knee replacement surgery, but up to 20% result in dissatisfaction due to pain or instability. 
[Animation image changes to show a lightning bolt, an upward arrow and a first aid symbol above text: Chronic Pain, High Case Loads, Hospitals, Under Pressure]
These issues require extensive ongoing care, putting enormous strain on the patient, surgeon and our healthcare system. 
[Animation image changes to show doctors holding and examining a cross section of a patient’s leg showing the knee joint pinpointed, and text appears: Manual Estimation]
Despite advancements in surgical technology, balancing soft tissue and ligaments still relies on surgeons manually estimating by feel and experience. 
[Animation image changes to show a column graph for Knee Replacements, growing from Today and up to 2030 by +40%]
With knee replacements expected to rise over 40% by 2030 we need more accurate solutions. 
[Animation image changes to show a doctor holding a clamp on the cross-section patient’s knee, and the camera pans in on the clamp linking it to text boxes: Smart Clamp, Real Time Force Measurement, Single User Operation, Stable and Direct Femur Grip]
Our innovative Smart Clamp works alongside robotic systems and enables surgeons to achieve greater precision. 
[Animation image changes to show a doctor reviewing a computer screen showing a line graph of force to ligament strain on the left and a knee joint on the right]
The Smart Clamp stabilises the knee during surgery and measures the forces going through the soft tissue, providing surgeons real time insights and enabling them to make more informed decisions on knee stability. 
[Animation image changes to show a shooting target, a clock and a tick symbol above text: Higher Accuracy, Faster Recovery, Happier Patient]
The result? Surgeons operate with greater confidence, patients recover quicker with better results and healthcare systems reduce long term care costs. 
[Image changes to show the Viortec logo above text: Innovative Surgical Solutions,  Find out more at viortec.com]
At Viortec, we're revolutionising the future of orthopaedic surgery, and Smart Clamp is just the beginning. 
[Image changes to show Dr Catherine Galvin walking on stage, talking to the audience in the foreground, and a new slide shows the Viortec logo above text: Innovative Surgical Solutions]
Dr Catherine Galvin: Last but not least. 
[The camera zooms in to a medium view of Catherine as she continues talking from centre stage, and points at the slide behind her, and text appears: Dr Catherine Galvin, Viortec]
Hello, everybody. I'm Catherine Galvin and together with my team here, Dr. Nicolo Malagutti and Jim McDougall, welcome to the world of Viortec. 
Before I say anything else about our technology, though, let me tell you a story. In 2016, I was doing a taekwondo demonstration to a group about this size and I was doing a fantastic but technically really tricky technique. 
[The camera zooms out as Cathrine continues talking from centre stage to the audience in the foreground]
And what I had to do was I had to take two steps forward and from an awkward stance, jump up in the air, do a beautiful twisting kick to the front with my left leg, back kick with my right leg, bring my feet hip width apart and land one step forward. 
[The camera zooms in to a medium view of Catherine as she continues talking from centre stage]
The kicks were amazing, the landing was catastrophic. I broke my knee and unfortunately that was the end of a 40 year career in taekwondo. 
[The camera zooms out as Catherine continues talking to the audience from centre stage, and a new slide shows hands holding a sore knee glowing red on the right, and text appears on the left: We have identified a massive opportunity to improve patient outcomes]
But what it means now is that I live with knee pain, and I know there are many people in this room that do the same thing, we live with knee pain. Because of my catastrophic injury I am heading towards a total knee replacement at some point, later hopefully rather than earlier, but that's where I'm heading. 
[The camera zooms in to a medium view of Catherine as she continues talking from centre stage]
And some of us in this room might be joining me, but I don't want to be that two or three people in ten that come out of that surgery still in pain with an unbalanced knee that's either too tight or too wobbly. I don't want to be those people. And you think, wow, there's an opportunity to improve that. And that's what we've been looking at. 
[The camera zooms out as Catherine continues talking to the audience from centre stage, and the slide changes to show doctors performing surgery on the right, and text appears on the left: The Issue, What’s driving poor outcomes?, There are significant technology gaps in the surgery]
We can see that there is poor outcomes that we can improve. So what have we done? 
[The camera zooms in to a medium view of Catherine as she continues talking from centre stage]
We can see in the surgery, in the environment, the operating theatre there is super high tech robotic and navigation equipment sitting next to tools from the 1900s and we could see there was a real disconnect. And so we decided to build a bridge and our first bridge is our smart clamp. 
[The camera zooms out as Catherine continues talking from centre stage, and a new slide shows symbols of a shooting target, a timer, a magnifying glass, a plus and a smiling face, and text appears: Viortech SmartClamp, Higher Accuracy, Faster Recovery, More Data, More Surgeries, Happier Patients]
So what our smart clamp does, and please come over and have a look - we brought a leg with us - what it does, it grabs the femur really securely and it enables the orthopaedic surgeon, man or woman, the orthopaedic surgeon to really do their soft tissue balancing as accurately as possible. And we're also providing them data on how much force they are putting on the knee. 
[The camera zooms in to a medium view of Catherine as she continues talking from centre stage]
We have been so lucky to have amazing collaboration, and we've now got two research agreements with a very large international orthopaedic manufacturer, Medacta. And over the life of Viortec, we've been working closely with the Trauma Orthopaedic Research Unit at the Canberra Hospital and been working with people in the ANU. 
[The camera zooms out as Catherine continues talking to the audience, and a new slide shows the rise in capital needed in 2023 compared to 2033 on the right, and text appears on the left: Market Size, A Growing Market, -Projected >50% increase in 10 years, - 85% of growth coming from US & EU, - Surgeons and hospitals struggling to keep up with demand, $10.9B, 2023, $16.9B, 2033]
Unfortunately, I'm not the only one who's going to need this surgery. The number of people who are going to knee replacement surgery, I'm not looking at anyone in particular, but it is growing. And in the next ten years the number of people having surgery is going to grow by over 50%. 
[The camera zooms in to a medium view of Catherine as she continues talking from centre stage]
So that is a lot of people who are going to need help. So will this clamp be ready when I'm needing that surgery? Well we're working on it. So this year we have submitted our TGA application. We have PCT, I think it says ICT on the slide but it's PCT patents have been filed. 
[The camera zooms out as Catherine continues talking to the audience from centre stage, and a new slide shows a timeline of the predicted journey of Viortec from 2024 to 2028+, and text appears: The Viortec journey now and into the future]
We literally today printed the clamps that will be used in a 40 knee study at the end of this year. So we are aiming to get into the market in 2026. 
[Image continues to show Catherine talking to the audience, and then the camera zooms in on Catherine, and a new slide shows profile photos and details of the six team members between text: A team of leading Bioengineers and Surgeons, Dr Catherine Galvin, Dr Tom Ward, Dr Nicolo Malagutti, Prof Paul Smith A.M., Jim Macdougall, Andy Kim]
I am so lucky to be working with a team of orthopaedic surgeons and engineers, where we start with an idea and we end up with a tool in surgery. 
So we are looking for support. We love collaboration. 
[Image continues to show Catherine talking from centre stage as she points to the right]
We're looking at this next stage so we want to commercialise so we're looking for about 500 million so bring out your cheque books, we’re over there, which would be great. 
[The camera zooms out as Catherine continues talking to the audience from centre stage, and a new slide shows a white screen with text: The Ask, We are looking for support to accelerate, $500,000, for SmartClamp commercialisation, Introduction, To industry participants and partners, Support, And engagements to achieve our vision, Advice, To keep us in the right track]
But we also love talking about our technology and having lots of advisers and mentors and people who want to join us on the journey. So please come and talk about what we're doing after this talk. 
[Image continues to show Catherine talking to the audience from centre stage, and the camera zooms in on Catherine talking, and a new slide shows a white screen with text: Help extend our healthy movement quality of life. Join us]
So imagine I'm on the operating table and I'm being wheeled into the surgery. I want to make sure that we have provided that orthopaedic surgeon with the best tools available, so he can produce the best surgical outcome possible for me and everybody having this surgery. We want to come out of this surgery, we want to be able to say we have extended our healthy movement quality of life. 
[The camera zooms out as Catherine continues talking to the audience from centre stage]
You don't want to be one of those people that say, I wish I invested in Viortec. 
[Applause can be heard and music plays as Catherine is exiting the stage to the left, walking across the room to the right, a new slide shows a black screen with the Australian National University logo]
[Image shows Tennille getting up from the audience and walking onstage from the right, and talking to the audience from centre stage, and a new slide shows the ON Accelerate 9 slide again]
Tennille Eyre: Congratulations, team. 
[The camera zooms into a medium view of as Tennille continues talking from centre stage]
Take a breath. 
Applause can be heard as Tennille smiles from centre stage]
Everyone, please, let’s give a big round of applause for the Accelerate 9 cohort. 
[Applause continues to be heard]
Your dedication and hard work has been nothing short of incredible. And also to those of you who had some technical glitches, credit to you on how you rolled with that. I know we do our best to try and prepare you, but absolute top notch, top notch. 
[Camera zooms out as Tennille continues talking to the audience, and a new slide shows a profile photo of Tennile on the left, and text appears on the right: Tennille Eyre, Program Director, ON Innovation Program, Impactful Leadership Award ON Accelerate 9]
And speaking of, there we go. 
[Tennille can be heard laughing briefly]
So I have the pleasure today of presenting an award to acknowledge that we have a particular participant in the program this year whose leadership skills have shone brightly throughout the program. 
[The camera zooms into a medium view of as Tennille continues talking from centre stage]
This particular participant has demonstrated vision, empathy and adaptability. It's important for us to recognise and reward these traits and this award is called the Impactful Leadership Award, and it includes a contribution to the individual's ongoing leadership development. 
[Camera pans right following Tennille as she walks to the podium and picks up papers and then moves back to centre stage, and she begins talking to the audience again]
So it is my great pleasure to announce the winner of the Impactful Leadership Award is Ella Casale from Elemental Therapeutics at the University of Melbourne. 
[Applause can be heard and music plays as the camera zooms out, and Ella can be seen walking onstage from the right to accept the award from Tennille at centre stage and a new slide shows text: Congratulations, Impactful Leadership Award Winner]
[The camera zooms into a medium view of as Tennille and Ella pose for a photo from centre stage]
We have a photo. 
[Image shows a photographer asking Tennille and Ella to come closer for more photos, and they continue smiling at the photographers talking photos]
Come forward, thank you. 
[Image shows Tennile and Ella turning to each other talking, and then Tennile pointing right as Ella exits to the right]
Congratulations. Yeah. Take a seat. Thank you. 
[Image shows Tennille laughing and then she begins talking from centre stage]
Congratulations, Ella. It's very, very well deserved. 
Now, I'm thrilled also to invite a special guest who's with us today. We partner every year with the Stanford Australia Foundation to grant a Stanford scholarship for someone in the cohort to attend the Stanford Graduate School of Business for someone in this particular cohort round who's constantly shown a remarkable entrepreneurial capacity. This scholarship acknowledges their commitment to program and to their venture, their mindset and adaptability to navigate ambiguity and we all know there's a lot of that but also while supporting others to build something great. 
[Image continues to show Tennille talking from centre stage as she points to the left]
So it's my pleasure to invite Roisin if you would come and join me up on stage. 
[Image continues to show Tennille talking from centre stage, the camera pans slightly right as Tennille exits right and reappears with an award, as Roisin Ryan appears on the left]
Roisin is from the Stanford Australia Foundation and will join me in presenting the award. 
[Laughter can be heard as the image shows Tennille handing the award to Roisin]
It's a heavy one, so. Yeah. 
[Image continues to show Tennille talking from centre stage and Roisin listening on the left holding the award, and then the camera zooms out, and a new slide shows Roisin’s photo and text appears: Roisin Ryan, Standford Australia foundation, Standford Australia Foundation Hawkins Ueland CSIRO Scholarship ON Accelerate 9]
Now, Roisin Ryan, we've been partnering, as you know, since 2017, and it's so incredibly exciting to know that we're going to continue that partnership moving forward. 
[The camera zooms in to a medium view of Tennille as she continues talking from centre stage and Roisin listening on the left holding the award]
We've so far issued eight scholarships to our participants in the ON Accelerate program. So allowing these alumni to experience the benefit of a program delivered by Stanford at their executive education together, SAF and ON obviously have really aligned goals, shared common missions to support and invest in the next talent and the pipeline of talent of Australian innovation. 
So before I announce the winner, Roisin and I would love to share our incredible gratitude and congratulations to you for all of your hard work. Obviously we can only award one, but I'm sure there are many of you who are very deserving. We will be continuing this partnership and we continue to look forward to supporting that growth. 
[Camera zooms out to show Tennille as she continues talking from centre stage and Roisin can be seen listening on the left, then Tenille and Roisin looking to the right and the same slide can be seen]
Now I'm very happy to announce that this year's scholarship winner is of the Stanford Australia Foundation Hawkins Ueland CSIRO scholarship - say that fast - and the winner is Brennen Mills from I-VADE at Edith Cowan University.
[Applause can be heard and music plays and Roisin walks to the right as Brennen enters the stage from the right and the camera zooms in on Roisin shaking Brennen’s hand] 
Dr Brennen Mills: Thanks so much for this. Thank you. 
[Image shows Brennen accepting the award and talking]
Thank you. Amazing.
[Image shows Tennile approaching from the left and then Tennille, Roisin and Brennen step toward the photographer and pose for photos]
Tennille Eyre: So we're gonna get a photo. We'll come stand at the front of the stage.
[Laughter can be heard as the photographer directs Brennen and Roisin to switch places and gesturing for them to step forward again]
Yes, yes. Thank you. Thank you. Take a seat. 
[Music plays and the image shows them posing, and then Tennille talking to Brennen as Roisin listens]
Brennen, would you like to say a few words?
Dr Brennen Mills: Oh, jeez. 
[Image shows Tennile and Roisin exiting to the left as Brennen looks surprised and continues talking from centre stage]
Oh, wow. They've turned my mic on without me even knowing.
Tennille Eyre: It's like they knew.
Dr Brennen Mills: Yeah, I know right. Oh my God. Yeah. Thank you so much. I'm still wrapping my head around what this actually means. It's so amazing. Yeah, but, amazing, the program has just been so great. I mean, all of us sitting here, we all just got so much out of it. So big, big thank you to the CSIRO, Tennille, Emily, everyone, my amazing team we've you know we've been doing this for a while now and I just love it more and more every day and getting on with you guys and getting the work done for for this amazing initiative. I'll keep rambling so I'll leave. But no, thank, thank you again. I'm so honoured. Thank you.
[Applause can be heard as the Camera pans right following Brennen exiting to the right, and then the camera pans left on to Tennille as she begins talking]
Tennille Eyre: Congratulations, Brennen and just to be careful trying to get that home in your luggage. 
[Laughter can be heard as Tennille continues talking from centre stage]
Now, of course I do have some thank yous. And as I mentioned, we have an incredible community of supporters in the program. 
[The camera zooms out to show Tennille talking from centre stage to the audience in the foreground, and a new slide shows two profile photos of the ON Accelerate 9 Facilitators, and text appears: David Ireland, Lead Facilitator, Andy Lamb, Facilitator]
David and Andy, would you like to stand? I would love for us to please say thank you. 
[Applause can be heard as David Ireland and Andy Lamb stand in the audience, and then turn and bow to the audience  before returning to their seats, and then camera zooms in on Tennille talking]
They were tick tacking on exactly what they were going to do. I'm a bit disappointed there weren't some some great motions, but thank you so much for your guidance and counsel for the teams that are coming through the program, obviously, and our team as well. We are incredibly thankful for your time, your commitment, your energy, some more than others and your contributions to the cohort. 
We also have someone who's not up on screen, Poppy Sykes. So Poppy is the manager of the program and also co-facilitated the ON Accelerate program at the start. She's going through a pretty transformative change at the moment, she’s at home raising two under two. So we want to also share our thanks with Poppy and but also congratulations on the birth of her recent daughter. 
[Applause can be heard as the camera zooms out as Tennille continues talking to the audience, and a new slide shows many profile photos of the “ON Accelerate 9, Coaches and Experts”]
And a huge thank you to our incredible network of coaches and mentors and experts. 
[The camera zooms in to a medium view of Tennille as she continues talking from centre stage]
ON believes in a raise all the boats approach and this incredible group here but also there's many more of you here in the room that support programs like our ON Prime, your collective effort, knowledge and wisdom solves this research translation gap. It is how we're going to continue helping translate this technology from mind to market. And we can't do it alone and we all need to continue working together to make this change so thank you all so much for being here. And without always wanting a lovely sort of stage reference, you're inviting people into the room where the conversation happens. 
[The camera zooms out as Tennille continues talking to the audience from centre stage, and a new slide shows many logos of the “ON Innovation Program Supporting Institutions”]
We've got an incredible group of research institutions that partner with us as well. 
[The camera zooms in to a medium view of Tennille as she continues talking from centre stage]
And so a huge thank you to all of you, I think there's 63 overall who have participated in our programs across the spectrum. But I also want to say a thank you and a welcome to anyone who's new to this community. We always have some new faces joining us. And again, as I said earlier, this is possibly one of the warmest, kindest and friendliest communities you can join and so welcome to you as well. Any new institutions? We have a couple of new ones on the screen. New investors, industry representatives and of course a huge thank you to our incredible tech transfer officers, commercialisation specialists and supporters who help and make this happen. Without you, this technology wouldn't get out of the institutions and into the world making a real world impact so a huge thank you to you. We all, thank you, thank you and grateful to everyone who's come and joined us today. I know it's always difficult to find time in your diary to escape. But for those of you who've been here for a while, I also want to recognise and thank you. I know you feel like a bit of the furniture around here but you are all incredibly valued and appreciated. 
[The camera zooms out as Tennille continues talking to the audience from centre stage, and a new slide shows profile photos of 18 “ON Accelerate Program Team” members]  
And a huge thank you to the faces on the screen. Many of you will know them as the ON team, my incredible people I get to do this work with every day. 
[The camera zooms in to a medium view of Tennille as she continues talking from centre stage]
They're nothing but a joy to work with, work for and I'm sure you would all agree with that sentiment. They’re an incredible team that help and they're driven by passion to see and empower others. Specifically, I do want to shout out to Emily, to Carol, Andrew, he’s probably sneaking around in the background, to Penny and Ange and Laura. Your guidance, your support and your empowering behaviours and mindset is everything to the teams that come through the program, I'm sure they join me in saying they wouldn't be able to do this without you and neither would I. And of course, thank you to everyone who's here today. Before we finish, there is immense potential from those who are here in the room today. Some PhDs who are going through the next stages of their journey, all the way through to those who have been on this journey before. You all play a pivotal role in supporting each other and the heroes of our innovation ecosystem. 
[The camera zooms out as Tennille continues talking to the audience from centre stage, and a new slide shows a blue screen two QR codes, and text appears: ON Prime 18, ON Accelerate 10, Join the next wave of innovators!]
But we're always, what's next. So ON Accelerate 10 applications are now about to be open. 
[The camera zooms in on the slide with the two QR codes]
So on screen there's a QR code for expressing interest if you want to join us on the next cohort of ON Accelerate. 
[Image changes to show a medium view of Tennille as she continues talking from centre stage]
Speak to anyone who came through the program this round and I'm sure they will tell you how fantastic it was, eye opening I'm sure, but also very fantastic. But perhaps you might know someone who's not yet there. Do they need to have some conversations in the market to validate their opportunity in technology? 
[Image changes to show the slide with two QR codes again]
That's where ON Prime comes in as well. So ON Prime before ON Accelerate is a great opportunity to help those teams who are much earlier on their journey. 
[Image changes to show a medium view of Tennille as she continues talking from centre stage]
So I'll leave those up there just for another moment. 
To our research leaders and university partners, if you've been wondering whether or not ON is the right program for you come and chat to any of our team and we'll help you. We'll help you along that that decision journey to our alumni, our facilitators and our program team, thank you so much for supporting everything we do here at ON. 
[The camera zooms out as Tenille continues talking from centre stage to the audience in the foreground, and then the camera zooms in on Tennille, and a new slide shows a blue screen with text: ON Accelerate 9, Showcase 5 June 2025]
Now we are so incredibly community minded and community driven, but that's because of all of you and all of your contributions in the program. 
[Image shows Tennille as she continues talking from centre stage, and points to the right]
Continue to please offer your advice, your connections and potentially your funds according to your cheque books to the teams that spoke on stage before your contribution matters. Now we're about to close and wrap up the day. So I do want to say let's give the current graduating ON Accelerate 9 cohort another incredible round of applause. 
[Applause can be heard as Tennille continues talking from centre stage]
And I know I'm standing between you and some incredible conversations and networking, but I do want to ask the Accelerate 9 cohort to come up on stage and get a photo, it’s very hard to wrangle all of those cats, before you move forward to networking this evening. So thank you everyone. Please enjoy a drink, some canapés and have a fantastic evening. Thank you for coming tonight and I'll call the cohort up onto stage. 
[The camera zooms out as Tenille continues talking from centre stage to the audience in the foreground]
Thank you everyone.
[Applause can be heard as audience members begin standing up] 
[Music plays as the image changes to show a white screen with the CSIRO logo above text: Australia’s National Science Agency]